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ABSTRACT 
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, creates an urgent need 
for identifying molecular mechanisms that mediate viral entry, propagation, and tissue pathology. 
Cell membrane bound angiotensin-converting enzyme 2 (ACE2) and associated proteases, 
transmembrane protease serine 2 (TMPRSS2) and Cathepsin L (CTSL), were previously identified 
as mediators of SARS-CoV2 cellular entry. Here, we assess the cell type-specific RNA expression 
of ACE2, TMPRSS2, and CTSL through an integrated analysis of 107 single-cell and single-nucleus 
RNA-Seq studies, including 22 lung and airways datasets (16 unpublished), and 85 datasets from 
other diverse organs. Joint expression of ACE2 and the accessory proteases identifies specific 
subsets of respiratory epithelial cells as putative targets of viral infection in the nasal passages, 
airways, and alveoli. Cells that co-express ACE2 and proteases are also identified in cells from 
other organs, some of which have been associated with COVID-19 transmission or pathology, 
including gut enterocytes, corneal epithelial cells, cardiomyocytes, heart pericytes, olfactory 
sustentacular cells, and renal epithelial cells. Performing the first meta-analyses of scRNA-seq 
studies, we analyzed 1,176,683 cells from 282 nasal, airway, and lung parenchyma samples from 
164 donors spanning fetal, childhood, adult, and elderly age groups, associate increased levels of 
ACE2, TMPRSS2, and CTSL in specific cell types with increasing age, male gender, and smoking, 
all of which are epidemiologically linked to COVID-19 susceptibility and outcomes. Notably, 
there was a particularly low expression of ACE2 in the few young pediatric samples in the analysis. 
Further analysis reveals a gene expression program shared by ACE2+TMPRSS2+ cells in nasal, 
lung and gut tissues, including genes that may mediate viral entry, subtend key immune functions, 
and mediate epithelial-macrophage cross-talk. Amongst these are IL6, its receptor and co-receptor, 
IL1R, TNF response pathways, and complement genes. Cell type specificity in the lung and 
airways and smoking effects were conserved in mice. Our analyses suggest that differences in the 
cell type-specific expression of mediators of SARS-CoV-2 viral entry may be responsible for 
aspects of COVID-19 epidemiology and clinical course, and point to putative molecular pathways 
involved in disease susceptibility and pathogenesis.   
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INTRODUCTION 
 
COVID-19 is a global health threat due to its rapid spread, morbidity, and mortality. Despite 
progress in viral identification, sequencing of the full viral genome, creation of initial diagnostics, 
and the development of therapeutic hypotheses, many outstanding hurdles remain. These include 
deciphering the basis of the increased risk associated with certain demographic groups and 
identifying molecular mechanisms of disease pathogenesis.  
 
The clinical presentation and transmission of COVID-19 is complex. Common symptoms include 
fever, cough, shortness of breath, chest pain, malaise, fatigue, headache, myalgias, anosmia, and 
diarrhea, while laboratory and radiographic findings include lymphopenia and ground-glass 
opacities on chest imaging, respectively1–8. Of an initial cohort of 1,099 hospitalized patients 
diagnosed with COVID-19, many developed diffuse alveolar damage (DAD) 1, pneumonia 
(79.1%), not infrequently complicated by acute respiratory distress syndrome (ARDS, 3.4%), and 
shock (1.0%), with 5.0% of patients requiring ICU admission and 2.2% requiring ventilation4. As 
the number of patients has surged, multi-system pathologies have been increasingly described, 
including kidney injury9, liver injury, gastrointestinal symptoms4, cardiac injury and 
dysfunction2,5,10, and multiorgan failure1–4. In addition to nasal and throat secretions, SARS-CoV-
2 RNA has also been detected in saliva and stool specimens10,11, suggesting possible alternative 
routes of transmission beyond respiratory droplets12,13. SARS-CoV-2 may also infect the testis, 
similarly to SARS-CoV14,15. Vertical transmission from mother to fetus remains a possibility. At 
least five neonates born to pregnant women with COVID-19 pneumonia were reported to test 
positive for SARS-CoV-2 infection after birth16–18 and other studies report newborns with elevated 
virus-specific antibodies to SARS-CoV-2 born to mothers with COVID-1916,19. However, several 
other studies have thus far failed to find evidence for intrauterine transmission from pregnant 
women with COVID-19 to their newborns in cohorts as large as 38 patients20–22. Additionally, 
newborns from 9 COVID-19 patients who had cesarean deliveries in their third trimester tested 
negative for SARS-CoV-217.  
 
There is substantial variation in the clinical consequences of infection across individuals, ranging 
from asymptomatic carrier status to death. It has been suggested that undocumented subclinical 
infection contributes to the rapid dissemination of the virus23. As of April 14, 2020, COVID-19 
has caused 1,970,225 confirmed infections and 124,544 deaths worldwide 
(https://coronavirus.jhu.edu/map.html). While true case fatality rate (CFR) is difficult to assess 
early in an epidemic24–26, estimates from modeling studies range from 0.9% - 3.3%27,28. Disease 
severity and mortality rates show a striking rise with age29, with CFR estimates ranging from 
<0.1% for patients under 30 years old to >10% for those over 7024, with a slightly higher incidence 
and mortality in men4,30. Children are significantly less likely than adults to develop severe disease, 
and reported pediatric deaths are rare31. Smoking is most likely associated with more severe 
disease4,32. Finally, adults with pre-existing cardiovascular disease and acute myocardial injury 
have higher rates of disease acuity and death33,34. 
 
The coronavirus non-segmented, positive sense RNA genome of ~30 kb contains coding regions 
for the expression of structural proteins including spike (S), envelope (E), membrane (M), and 
nucleocapsid (N) proteins. Virion recognition of host cells is initiated by interactions between the 
S protein and its receptor35. ACE236–38, an essential regulator of the renin-angiotensin system39, is  
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the receptor for both SARS-CoV40 and SARS-CoV-2. The receptor-binding domain of the SARS-
CoV-2 S-protein has a higher binding affinity for human ACE2 than SARS-CoV36,41, whereas the 
interaction with CD147 (encoded by the gene BSG), another reported receptor for the SARS-CoV-
2 S-protein, is weak (CD147: Kd, 0.185 µM vs hACE2: Kd, ~15 nM)42. Following receptor 
binding, the virus gains access to the host cell cytosol through acid-dependent proteolytic cleavage 
of the S protein. For SARS-CoV, a number of proteases including TMPRSS2 and CTSL cleave at 
the S1 and S2 boundary and S2 domain (S2’)43 to mediate membrane fusion and virus infectivity. 
For SARS-CoV-2, both pharmacological inhibition of endogenous TMPRSS2 protein and 
TMPRSS2 overexpression support a role for TMPRSS2-mediated cellular entry37,44. 
 
The identification of the specific cell types that can be infected by SARS-CoV-2 will inform our 
understanding of disease transmission and pathogenesis, which are often cell context-specific. 
Studies suggest that key infection routes involve the nasal passages, airways, and alveoli, where 
epithelial cells play a key barrier role. Identifying putative target cells in other organs could inform 
our understanding of extra-pulmonary COVID-19 associated organ failure or of potential placental 
transmission. Early analyses of the Human Lung Cell Atlas revealed that some of the cells of the 
nasal passages, airways, alveoli, and gut co-express ACE2 and TMPRSS245,46.  
 
Here, we perform integrated analysis of 107 single-cell and single-nucleus RNA-Seq studies, 
including 22 studies of the lung and airways, and 85 additional studies of other diverse tissues, 
spanning both published and unpublished datasets. We comprehensively define the expression 
patterns of the ACE2 viral receptor and accessory proteases genes. We test how their expression is 
related to age (from prenatal to old age), sex, and smoking status. We identify gene expression 
programs associated with cells that can be infected by the virus and compare these programs across 
specific cell types, organs, and species. To further inform future studies, we assess the conservation 
of these human features in mouse models and explore the expression of other proteases that may 
play a role in the viral replication cycle.  
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RESULTS 
 
A cross-tissue survey identifies dual-positive ACE2+TMPRSS2+ cells in nasal, airway, 
alveolar, and intestinal epithelia, as well as in other organs associated with COVID-19 
pathology or transmission   
 
Previous analyses of Human Cell Atlas datasets established that ACE2, the viral receptor, and one 
of its entry-associated proteases, TMPRSS2, are expressed in nasal, lung, and gut epithelial cells45. 
Specifically, nasal goblet cells and multiciliated cells comprised the highest fraction of dual-
positive ACE2+TMPRSS2+ cells45, consistent with a plausible role for a nasal viral reservoir that 
supports transmissivity. In the distal lung, co-expression occurred in AT2 cells45,47,48. Previous 
surveys across other tissues also showed a relatively high portion of ACE2+TMPRSS2+ cells within 
colonic enterocytes, another potential viral reservoir that promotes viral transmission49.  
 
To perform a comprehensive survey, we enumerated the proportion of dual-positive 
ACE2+TMPRSS2+ cells and ACE2+CTSL+ cells50 across 92 human studies (including seven of the 
lung and airways) with single-cell or single-nucleus RNA-seq (sc/snRNA-seq) (Fig. 1, Methods, 
Supplementary Table 1 and 2). These included a large survey of published datasets from diverse 
tissues, which we assigned to five broad cell categories, (Fig. 1a,b, Extended Data Fig. 1,2, 
Supplementary Table 1). We further analyzed more finely annotated published and unpublished 
datasets (Methods, Fig. 1c,d, Supplementary Table 3). Consistent with previous reports45, dual-
positive ACE2+TMPRSS2+ cells in the proximal airways were largely secretory goblet and 
multiciliated cells, and dual-positive cells in the distal lung were largely AT2 cells (Fig. 1c, 
Extended Data Fig. 3a). 
 
ACE2 expression in secretory (especially goblet) and AT2 cells is also supported by scATAC-seq 
from the primary carina and subpleural parenchyma, respectively (Fig. 2, n=3 samples per 
location, n=1 patient), showing accessibility at the ACE2 locus in a portion of AT2 cells (10.8%, 
364 out of 3,371 cells, Methods), as well as secretory and multiciliated cells, and to a lesser extent 
some basal and tuft cells (Fig. 2a-c). The proportion of AT2 cells with an open ACE2 locus is 
somewhat higher than of ACE2+ AT2 cells by scRNA-seq in the same patient and region (pleura: 
10.8%, 364 out of 3,371 cells vs. 6.2%, 199 out of 3,215 cells). Cells with accessible chromatin at 
both the ACE2 and TMPRSS2 loci were also most commonly found in epithelial cells, especially 
AT2 cells (Fig. 2d, 4.98%, 168 of 3,371 AT2 cells from a subpleural sample; comparable to 3.9%, 
124 of 3,215 in matched scRNA-Seq), secretory cells (6.72%, 8 of 119 secretory cells from small 
airway of the subpleural region, and 6%, 12 of 200 secretory cells from primary carina of the large 
airway), and multiciliated cells (6.61%, 32 of 484 multiciliated cells from subpleural sample, and 
4.81%, 31 out of 644 multiciliated cells from primary carina).  
 
There were dual-positive ACE2+TMPRSS2+ cells in tissues beyond the respiratory system (Fig. 
1a-c), including enterocytes, pancreatic ductal cells, prostate luminal epithelial cells, 
cholangiocytes51, oligodendrocytes in the brain, inhibitory enteric neurons, heart 
fibroblasts/pericytes52, and fibroblasts and pericytes in multiple other tissues (Fig. 1c). 
ACE2+TMPRSS2+ epithelial cells were most prevalent (in order) within the ileum, liver, lung, nasal 
mucosa, bladder, testis, prostate, and kidney (Fig. 1a). Enterocytes had a substantial proportion of 
dual-positive cells (Fig. 1c), and are possibly part of a renin-angiotensin multicellular circuit53. In 
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line with the kidney’s role in the renin-angiotensin-aldosterone system, dual-positive cells are 
enriched in the proximal tubular cells and in principal cells of the collecting duct (Fig. 1a,c). 
Interestingly, brain oligodendrocytes, multiciliated and sustentacular cells in olfactory epithelium, 
AT1 cells in non-smoker lung, and ductal cells in pancreas – all ACE2+TMPRSS2+ – were also all 
enriched for MYRF, a transcription factor necessary for myelination in the brain and sufficient to 
induce expression of the myelin proteins MOG (myelin oligodendrocyte glycoprotein) and MBP 
(myelin basic protein)54. ACE2+CTSL+ cells were enriched in additional subsets, associated with 
COVID-19 pathology, most notably the olfactory epithelium, ventricular cardiomyocytes, heart 
macrophages, and pericytes in multiple tissues, including the heart, lung, and kidney (Fig. 1d).  
 
The presence of dual-positive cells in the lung, heart, and kidney may reflect that cells in these 
organs may be direct targets of viral infection and pathology5,55. Dual-positive cells in the 
sustentacular and basal cells of the olfactory epithelium (Fig. 1c) may be associated with a loss of 
the sense of smell56. Dual-positive cells in the corneal and conjunctival epithelium, may contribute 
to viral transmission4,57. Dual positive cardiomyocytes may be related to “direct” cardiomyocyte 
damage (see Tucker et al. companion manuscript58), whereas heart pericytes may indicate a 
vascular component to the cardiac dysfunction, and could contribute to increased troponin leak in 
patients without coronary artery disease. Notably, ACE2-expressing heart pericytes in another 
dataset (Tucker et al) is even higher (30%) than any other tissue dataset analyzed here (max. 21.7% 
in kidney, Extended Data Fig. 4).  Despite the lymphopenia observed with COVID-192,4,59,60, we 
did not typically observe ACE2 mRNA expression in scRNA-seq profiles in the bone marrow or 
cord blood (Fig. 1a,b), although there was ACE2 expression in some tissue macrophages, 
including alveolar and heart macrophages (Extended Data Fig. 4). Further studies of ACE2 RNA 
and protein expression in COVID-19 disease tissue will help elucidate its expression in immune 
cells61.    
 
Validation of ACE2, TMPRSS2 and CTSL mRNA and protein expression in airway and 
alveolar epithelium 
To validate our findings from scRNA-seq analysis and to determine the spatial expression patterns 
of ACE2, TMPRSS2, and CTSL, and their corresponding proteins we performed fluorescence in 
situ hybridization and immunohistochemistry on tissue sections of airway and alveoli from healthy 
donor lungs that were rejected for lung transplantation.  
First, we performed triple fluorescence in situ hybridization to identify ACE2, CTSL and TMPRSS2 
on alveolar sections. We observed co-expression, albeit at low levels, of all three genes in alveolar 
cells (Fig. 1e). We then performed co-staining with cell type-specific markers. We observed ACE2 
transcripts in a subset of type 2 (AT2) cells identified by canonical AT2 protein markers, HTII-
280 and pro-SFTPC (Fig. 1f,g). Similarly, we observed TMPRSS2 gene expression in HTII-280+ 
AT2 cells (Fig. 1f). Immunostaining for TMPRSS2 protein further confirmed AT2 cell expression 
(Extended Data Fig. 5a). We also observed TMPRSS2 protein expression at low levels in some 
AT1 cells identified by the canonical AT1 protein marker AGER (Extended Data Fig. 5a). Of 
note, some non-epithelial cells also expressed these three genes. We further validated the 
expression of ACE2 by bulk mRNA-seq in sorted AT2 cells, including those from long-term 
cultured alveolar organoids (Extended Data Fig. 5b). We then performed immunohistochemistry 
and deployed three different available putative ACE2 antibodies to establish ACE2 protein 
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expression (Supplementary Table 4). One of these 3 antibodies, the one used previously to 
functionally block cellular viral entry, specifically labeled adult pro-SFTPC-positive AT2 cells 
(Extended Data Fig. 5c). As a cautionary note, the lack of agreement between antibody staining 
patterns suggests that some of these antibodies may be non-specific. 
Previous studies have revealed that ACE2 is highly enriched in mucous cells of the nasal and lower 
respiratory tract epithelium . In healthy lungs, both large and small airways contain mucous cells 
in surface airway epithelium, albeit at low numbers. However, submucosal glands (SMGs) that 
reside deep within the airway tissues are composed of abundant mucous cells. To test whether 
these mucous cells also express ACE2, TMPRSS2, and CTSL, we performed an integrated analysis 
on scRNA-seq datasets obtained from microdissected SMGs of the healthy donors. We observed 
overlapping expression and relatively high enrichment of AEC2, TMPRSS2 and CTSL in mucous 
cells of the SMGS (Extended Data Fig. 5e). In situ transcript analysis for ACE2 further confirmed 
the presence of transcripts in acinar epithelial cells of the SMGs (Fig. 1h), and cells expressing 
ACE2 in the large airway epithelium (Fig. 1i). 
ACE2 and TMPRSS2 expression in airway epithelial and AT2 cells increases with age and is 
higher in men, and airway epithelial cell expression increases with smoking 
We next sought to understand how the expression of each of these three key genes -- ACE2, 
TMPRSS2, and CTSL -- in specific cell subsets may relate to three key covariates that have been 
associated with disease severity: age (older individuals are more severely affected), sex (males are 
more severely affected), and smoking (smokers are more severely affected)62. We integrated 
samples across many studies, as no single dataset generated to date is sufficiently large to address 
this question. We assembled 22 datasets (Supplementary Table 2, Supplementary Data File 
D3), comprised of 1,176,683 cells from 164 individuals, spanning 282 healthy nasal, lung, and 
airway samples profiled by scRNA-seq or snRNA-seq from either biopsies, resections, entire lungs 
that could not be used for transplant, or post mortem examinations, allowing us to study a diversity 
of respiratory regions and cell types (Fig. 3a). These included 6 published datasets63–68 and 16 
datasets that are not yet published69–73. In the case of unpublished data, we only obtained single-
cell expression counts for the three genes, as well as the total UMI counts per cell, cell identity 
annotations, and the relevant anonymous clinical variables (age and sex, as well as smoking status 
when ascertained). Cell identity annotations were manually harmonized using an ontology with 
three levels of annotation specificity (Fig. 3b, Supplementary Table 2); focusing on levels 2 and 
3 allowed us to include a large number of datasets, while retaining relatively high cell subset 
specificity (Fig. 3a,b). To facilitate rapid data sharing, we analyzed data pre-processed by each 
data-generating team at the level of gene counts, using total counts as a size factor. We used 
Poisson regression (diffxpy package; Methods) to model the association between the expression 
counts of the three genes and age, sex, and smoking status, and their possible pair-wise interactions 
(Fig. 3c), using total counts as an offset, and dataset as a technical covariate to capture sampling 
and processing differences. It should be noted that modeling interaction terms was crucial as their 
omission resulted in reversed effects for age and sex for particular cell types (Discussion). This 
model was fitted to non-fetal lung data (761,693 cells, 165 samples, 77 donors, 10 datasets) within 
each cell type to assess cell-type specific association of these covariates with the three genes. To 
further validate sex and age associations, we fit a simplified version of the model without smoking 
status covariates to the full non-fetal lung data (986,342 cells, 225 samples, 125 donors, 16 
datasets). 
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Uncertainty is challenging to model in our single-cell meta-analysis as variability exists on the 
levels of both donors and cells. For simplicity, we modeled the overall variance with both 
contributions covered implicitly by treating each cell as an independent observation. As cells from 
the same donor cannot be typically regarded as independent observations, this can result in inflated 
p-values, especially when there are few donors for a particular cell type. To counteract this 
limitation, we employed three approaches: (1) We used a simple noise model (Poisson) to reduce 
the chance of overfitting donor variability to obtain spurious associations; (2) We confirmed 
significant associations from the single-cell model in a pseudo-bulk analysis to ensure effect 
directions are consistent when modeling only donor variation (Methods, Fig. 3d, Extended Data 
Fig. 6, 7, 8, Supplementary Data D1); and, (3) We investigated whether significant associations 
change direction when holding out any one dataset to ensure that the effect is not dominated by 
the inclusion of many cells from only one source (Methods, Fig. 3f, Supplementary Data D1). 
We regarded an association that passes all of these validations as a robust trend, while associations 
that appear dominated by a single dataset (often because this dataset is a major contributor of a 
given cell type) were denoted as indications. 
 
We focused on trends or indications in those cell types where both TMPRSS2 and ACE2 are 
predominantly expressed in the lung: airway epithelial cells (basal, multiciliated, and secretory 
cells), alveolar AT2 cells, and submucosal gland secretory cells (Fig. 3e). Strikingly, we find 
robust trends of ACE2 expression with age, sex, and smoking status in these cell types (Fig. 3d, 
Extended Data Fig. 6 and MALTE4): ACE2 expression increases with age in basal and 
multiciliated cells. ACE2 expression is elevated in males in airway secretory cells and alveolar 
AT2 cells. Furthermore, we find strongly elevated levels of ACE2 in past or current smokers in 
multiciliated cells (log fold change (log FC): 1.52, Fig. 3d). Significant associations of ACE2 
expression indicate increased expression with age in AT2 (largest age effect: slope of log 
expression per year of 0.020) and secretory cells, and increased expression of ACE2 in males in 
multiciliated cells. Further indications associate past or current smoking with decreased ACE2 
expression in AT2 cells, and increased ACE2 expression in basal cells. However, these last five 
indications are not robust trends and depend on the inclusion of a single dataset (Fig. 3f), often 
because that dataset contributes a large number of cells of a particular type. Specifically, when we 
held out the largest declined donor transplant dataset (Supplementary Table 2, “Regev-
Rajagopal”, most cells and most samples), a declined donor tracheal epithelium dataset (“Seibold”, 
Supplementary Table 2, most donors in the smoking analysis), or a further declined donor lung 
dataset (“Kropski-Banovich”, Supplementary Table 2) respectively, the effect is no longer 
present (Methods, Fig. 3f, Supplemenatry Data D1). 
 
The above trends and indications for sex and age were further validated in the simplified model on 
the full non-fetal lung dataset (Extended Data Fig. 8, Supplementary Data D2). With the 
exception of the age association in basal and secretory cells, all associations were found to be 
significant at a false discovery rate (FDR) threshold of 5%, confirmed by pseudo-bulk analysis, 
and were supported at least at the level of indication. Indeed, all robust trends were also supported 
as robust trends in the simplified model. Fitting the simplified model on the smoking data subset 
shows that modeling smoking status is crucial to detect the basal and secretory age association. 
Without modeling the effect of smoking status on basal and secretory cell ACE2 expression, this 
variance is captured as uncertainty against which the age effect is evaluated as not significant. 
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Taking into account smoking status is of particular importance as the effect sizes associated with 
smoking tend to be much larger than age effects, and tend to be larger than sex effects. For 
example, in multiciliated cells the effect sizes assigned to smoking status, sex, and age associations 
with ACE2 expression are β=1.52, β=0.51, and β=0.0107 respectively, where β represents the log 
FC and the slope of log expression per year. 
 
Examining joint trends of ACE2 and the protease genes within the same cell type, there are 
indications of up-regulation of both ACE2 and TMPRSS2 in multiciliated cells (ACE2 indication 
dependent on “Seibold” dataset) in males and with age (both indications dependent on “Regev-
Rajagopal” dataset). In AT2 cells, there is an indication of joint up-regulation of ACE2 and 
TMPRSS2 with age (dependent on “Regev-Rajagopal” dataset), and an indication of ACE2 and 
CTSL down-regulation in smokers (dependent on “Kropski-Banovich” dataset). All above joint 
trends for age and sex covariates were confirmed on the full non-fetal lung data using the simple 
model without smoking covariates. 
 
In aggregate, elevated levels of cell-type specific ACE2 and associated proteases are correlated to 
increasing age, in smokers, and in males. 
 
Distinctive changes in ACE2+TMPRSS2+ expression patterns during human development 
and very low expression in infants and young children  
 
The age associations highlighted particularly low expression in samples from very young children 
(newborn to 3 years old). As reports suggest that most infants and young children cases do not 
display severe disease11,74, we inspected the subsets of studies of human development and pediatric 
samples from our integrated analysis (Supplementary Table 2). These included cells from 12 first 
trimester samples (8 donors) of fetal lung (8.5 weeks post conception; wpc), 29 fetal lung samples 
(26 donors) from the second trimester (13-24 weeks)68, 13 lung samples (10 donors) spanning from 
third trimester premature births (n=4), full term newborns (n=1), ~3-month old (n=4), 3-year-old 
(n=3), and 10-year-old (n=1) children. Because the number of samples here is small, all 
observations must be interpreted with caution. 
 
The extent of ACE2 expression in lung cells changes during development (Fig. 3g, 
Supplementary Table 5). There are dual-positive cells present in the very early first trimester 
lungs by scRNA-seq, and some ACE2 expression in epithelial cells in the second trimester samples 
(Extended Data Fig. 3a,b). Notably, spatial transcriptomics of 8.5 pcw fetal lung did not capture 
any ACE2 expression (data not shown). In lungs from third trimester pre-term births, ACE2 
expression is high, with ACE2+TMPRSS2+ cells observed in alveolar AT2 cell populations 
(Extended Data Fig. 3b).  
 
Strikingly, ACE2 expression is very low in normal lungs of newborns, the one ~3 months’ lung 
sample, and the 3-year-old lungs (Fig. 3g). This is further supported by single-cell chromatin 
accessibility by transposome hypersensitive sites sequencing (scTHS-Seq75) from human pediatric 
samples (full gestation, no known lung disease) collected at day 1 of life, 14 months, 3 years, and 
9 years (n=1 at each time point) (Extended Data Fig. 9a). ACE2 gene activity scores (Methods), 
when present, were in the AT1/AT2 population, but no signal was present at birth, it was low in 
the 9-year-old and 3-year-old sample, and higher in the 14 month-old (Extended Data Fig. 9b-d). 
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Notably, immunohistochemistry (IHC) of the ~3 month-old infant lung also showed fewer ACE2-
immunoreactive AT2 cells (Extended Data Fig. 5d).  
 
We also assessed whether ACE2, TMPRSS2, and CTSL are expressed in the human placenta during 
pregnancy, using data from three published scRNA-seq studies: two from the first trimester 
(64,000 cells and 14,000 cells) and one from full-term placenta (20,518 cells)76–78. ACE2 was 
expressed (1.4%) in maternal decidual/stromal cells, maternal pericytes, and fetal extravillous 
trophoblasts, cytotrophoblasts, and syncytiotrophoblast in both first-trimester and term placenta 
(Fig. 1d). Note that there was little expression of TMPRSS2 (0.2%) in the placenta and accordingly 
few ACE2+TMPRSS2+ dual-positive cells (as we previously reported45). However, CTSL is 
expressed in most cells (56%) in the maternal-fetal interface, and there are ACE2+CTSL+ dual-
positive cells (1.3%) among maternal decidual/stromal cells, pericytes, and fetal trophoblasts 
(HLA-A, B negative) in both first-trimester and term placentae.  
 
Overall, these patterns may be important in understanding why children are more resistant to 
COVID-19 and and in considering risk during pregnancy. 
 
An immune gene program associated with ACE2+TMPRSS2+ expression in airway, lung and 
gut cells  
 
Our Human Lung Cell Atlas analyses have revealed immune signaling genes that co-vary with 
ACE2 and TMPRSS2 in airway and lung cells45,46. These analyses identified antiviral response 
genes that are enriched in ACE2+TMPRSS2+ cells (e.g., IDO1, IRAK3, NOS2, TNFSF10, OAS1, 
MX1), and suggested that ACE2 itself is interferon regulated45,46.  
 
To explore such gene programs in a broader context, we identified signatures for dual-positive 
ACE2+TMPRSS2+ cells compared to dual-negative ACE2-TMPRSS2- cells in the nasal epithelium, 
lung, and gut (Supplementary Tables 6, 7 8) with two complementary approaches. The first 
aimed to find features that characterize programs of dual positive cells that are shared by different 
cell types in one tissue (“tissue programs”). The second aimed to find features that are associated 
with dual positive cells compared to other cells of the same type, and may or may not be shared 
with other types (“cell programs”) (Methods). To infer tissue programs, we trained a random 
forest classifier to discriminate between dual-positive and dual-negative cells (excluding ACE2 
and TMPRSS2; 75:25 class balanced test-train split), generalizing across multiple cell types in one 
tissue, and ranked genes according to their importance scores in the classifier (Methods). To infer 
cell programs, we performed differential expression analysis between dual-positive and dual-
negative cells within each cell subset. We note that ACE2+TMPRSS2+ cells have more unique 
transcripts detected (Extended Data Fig. 10b): this can reflect a technical confounder, biological 
features, or both. We conservatively controlled for these differences (by sampling dual positive 
and dual negative cells from matched gene complexity bins; Methods; Extended Data Fig. 10b, 
Extended Data Fig. 11). Importantly, these methods do not assume that ACE2+TMPRSS2+ cells 
form a distinct subset within each cell type. Rather, our goal is to leverage the variation among 
single cells within a single type to identify gene programs that are co-regulated with ACE2 and 
TMPRSS2 within each expressing cell subset. 
 
Tissue programs (Fig. 4a, Extended Data Fig. 10a, Supplementary Table 7, 8) were enriched in 
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several pathways related to viral infection and immune response (see Fig. 4b, Extended Data Fig. 
10a for visualization of selected genes, and Supplementary Tables 6 for the full list). These 
include phagosome structure, antigen processing and presentation, and apoptosis. Among the 
tissue program genes we highlight: CEACAM5 (lung, nasal, gut programs) and CEACAM679 
(lung), surface attachment factors for coronavirus spike protein; SLPI (lung, nasal), a secreted 
protease inhibitor that is associated with virus resistance80; PIGR (lung, gut), the polymeric 
immunoglobulin receptor that may promote antibody-dependent enhancement via IgA81; and, 
CXCL17 (lung, nasal), a mucosal chemokine that attracts dendritic cells and monocytes to the 
lungs82. In addition, the tissue programs yielded multiple genes that are associated with cholesterol 
and lipid metabolic pathways and endocytosis (DHCR24, LCN2, FASN); high expression of both 
MHC I (B2M, HLA-B) and MHC II (HLA-DRA, DRB1, CTSS, CD74) pathways, expanding on 
prior evidence that AT2 cells can serve as antigen presenting cells in infection83; genes indicating 
preparation against cellular injury through ROS inhibition, preventing proteases, or through 
antiviral responses (interferons, extracellular RNAse, etc: PLAC8, TXNIP); complement genes 
(C3, C4BPA); genes involved in immune modulation (BTG1); and, tight junction genes (DST, 
CLDN3, CLDN4). 
 
The cell programs (Fig. 4c, Extended Data Fig. 11a,b, Supplementary Table 6) were enriched 
in many of the same genes and pathways as tissue-specific programs (Fig. 4d, Supplementary 
Table 6,7,8,9,10), and highlight a potential role for TNF signaling in ACE2 regulation. We first 
confirmed that the cell programs were not merely associated with the number of transcripts per 
cell (Extended Data Fig. 11c). While some genes were shared between the tissue and cell 
programs (e.g., many virus-related genes, such as CEACAM5, CXCL17, SLPI, and HLA-DRA), the 
cell programs further captured unique biological functions and activities. For example, dual 
positive lung secretory cells differentially expressed genes involved in TNF signaling including 
RIPK3, a key regulator of inflammatory cell death via necroptosis, previously implicated in SARS-
CoV pathogenesis84. Both lung dual positive secretory and multiciliated cells differentially 
expressed lysosomal genes (MFSD8, CTSS, CTNS, CTSH), potentially relevant for endo-
lysosomal entry of coronaviruses85. Dual positive AT1 cell programs included genes involved in 
immunoproteasome (PSMB8, PSMB9, Fig. 4c), class I and II antigen presentation (HLA-DMA, 
HLA-DRB5, HLA-DPB1, HLA-DRA, HLA-DPA1), and phagocytosis. Dual-positive nasal goblet 
cells differentially expressed several cytokines and chemokines, including granulocyte-colony 
stimulating factor (CSF3), which may impact hematopoiesis, the recruitment of neutrophils, and 
inflammatory pathology; CXCL1 and CXCL3, chemoattractants for neutrophils; interleukin-19 
(IL19), which induces the production of IL-6 and TNF86; and CCL20, which is upregulated by 
TNF 87. The AT2 cell program included the surfactant proteins, SFTPA1 and SFTPA2; the IL-1 
receptor (IL1R1), which may promote antiviral immune responses (below); and, multiple 
components of MHC-II (e.g., HLA-DPA1, HLA-DPB1), congruent with a role in antigen 
presentation.  
 
Cell programs from multiple tissues (Fig. 4c,d) included genes related to TNF signaling (e.g., 
BIRC3, CCL20, CXCL1, CXCL2, JUN, NFKB1), raising the possibility that anti-TNF therapy may 
impact the expression of ACE2 and/or TMPRSS2. Consistent with this hypothesis, ACE2 
expression in enterocytes was significantly lower in ulcerative colitis patients treated with anti-
TNF compared to untreated patients (mean = 0.22 and 0.13 log2(transcripts per 10,000 (TP10K)+1) 
in treated vs. untreated; adjusted P < 1e-3). However, we could not control for many important 
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features, including disease severity, which is strongly associated with anti-TNF treatment, raising 
the need for future work. Some of the genes are targets of known drugs88. For example, dual-
positive lung secretory cells expressed, in addition to ACE2 (targeted by ACE inhibitors), other 
drug targets, including C3, HDAC9, IL23A, PIK3CA, RAMP1, and SLC7A11. Other program 
genes were shown to interact with SARS-CoV-2 proteins via affinity purification mass 
spectrometry 89. Among those was GDF15, which was identified as a putative interaction partner 
for the SARS-CoV-2 protein Orf889, is a central regulator of inflammation90, and was a member 
of the dual-positive cell programs of both lung basal cells and nasal multiciliated cells.  
 
Some program genes may be particularly related to COVID19 pathological features and may 
indicate putative therapeutic targets. For example, MUC1 is especially highly induced in dual-
positive cells (in tissue and specific cell programs), which may be associated with respiratory 
secretions91. Importantly, the lung tissue and gut enterocyte programs include the gene encoding 
the IL6 co-receptor (IL6ST), and the AT2 cell program includes IL6. IL6 signaling has been 
implicated in uncontrolled immune responses in the lungs of COVID19 patients, elevated serum 
IL6 levels are associated with the need for mechanical ventilation92, and anti-IL6R antibodies 
(tocilizumab) are being tested for clinical efficacy in COVID-19 patients. Indeed, IL6ST and IL6 
are higher in dual positive vs. dual negative AT2 cells (Extended Data Fig. 11d), although IL6 
expression is relatively low in these cells from healthy tissue. Additional cell types, such as heart 
pericytes, are enriched for cells with co-expression of ACE2 with IL6R or IL6ST (Extended Data 
Fig. 12). 
 
The immune-like features of ACE2+ epithelial cells are also reflected in the regulatory features of 
the ACE2 locus by scATAC-Seq (Fig. 4f). Epithelial cells (AT1, AT2, secretory, multiciliated, 
ionocytes, and neuroendocrine cells) with open chromatin at the ACE2 locus show high motif 
activity scores93 for interferon-regulatory factors such as IRF1/7 (MA0050.1, adj p-val=0.02, 
MA0772.1, adj p-val=0.08), STAT1::STAT2 (MA0517.1, adj p-val=0.15), FOXA1 (MA0148.2, adj 
p-val=0.24) and FOXD2 (MA0847.2, adj p-val=0.27), compared to epithelial cells with no sign of 
open chromatin at the ACE2 locus, though the difference is statistically significant (adj p-val 
<0.05) only for IRF1. Interestingly, Forkhead Box Transcription Factors have been implicated in 
regulation of ACE2 transcription94. Note that because epithelial cells with an accessible ACE2 
locus tend to have a higher number of fragments in peaks than cells with inaccessible ACE2 
(Extended Data Fig. 11f), consistent also with higher UMIs in scRNA-seq, some of the cells with 
inaccessible ACE2 could be false negatives, reducing our power. 
 
Previous studies in the healthy lung predicted that interactions between AT2 cells and myeloid-
lineage macrophages may be important for immune regulation and surfactant homeostasis95. To 
explore this possibility, we predicted interactions between AT2 cells (in general, or 
ACE2+TMPRSS2+ dual-positives) and myeloid cells (Methods96), using our large declined donor 
transplant dataset (“Regev/Rajagopal”; 41 samples, 10 patients, 2-6 locations each). AT2 cells and 
myeloid cells were present in lung lobes samples from all 10 patients, whereas samples from 5 
patients contained both ACE2+TMPRSS2+ dual-positive AT2 cells and myeloid cells. We 
identified significant predicted interactions involving Oncostatin M (OSM), an IL6-type cytokine 
expressed by myeloid cells97, with the Oncostatin M Receptor (OSMR) and its paralog receptor 
LIF Receptor Subunit Alpha (LIFR) expressed in both for AT2 cells in general, and in double 
positive ones). Interactions involving the complement pathway were also predicted (for all AT2 
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and dual positives) between Complement C3 and C5 expressed by AT2 cells and their cognate 
receptor expressed in myeloid cells. Three samples had interactions between the IL1 receptor on 
AT2 cells and IL1B or IL1RN in myeloid cells. The IL1-receptor interactions were identified 
mostly (in 2 out of 3 samples) involving only dual-positive AT2 cells, suggesting a possible role 
of ACE2+TMPRSS2+ dual-positive cells in IL1-mediated processes. Finally, we identified 
interactions between CSF1, 2, or 3 expressed in AT2 cells (including double positives) and their 
receptors expressed in myeloid cells. These predicted interactions further support the previously 
identified roles for cross-talk between AT2 and myeloid cells, such as macrophages, in immune 
regulation (OSM, complement, IL1) and surfactant homeostasis (CSF), as previously 
highlighted95.  
 
Conserved expression patterns in mouse models  
 
We next asked whether human cell types of interest were present in animal models. While such 
analyses cannot address molecular compatibility (due to sequence variation in ACE2 across 
species, as shown for lower compatibility of SARS-CoV and mouse ACE298), they can help 
determine if dual-positive cells are present in commonly employed models, and if their 
characteristics, proportions, and programs are similar to those of their human counterparts. In a 
separate study46, our lung network showed strong similarities to the human data in a macaque 
model. Here, we focused on the more distant, but commonly used, mouse model.  
 
Ace2+Tmprss2+ and Ace2+Ctsl+ dual-positive cells were present primarily in club and multiciliated 
cells in the airway epithelia of healthy mice99 (Ace2+Tmprss2+ club 5.1% [4.7%, 5.4%] and 
multiciliated 2.8% [2.3%, 3.5%], Ace2+Ctsl+ club 11.1% [10.6%, 11.6%] and multiciliated 3.5% 
[2.9%, 4.3%]), consistent with the expression patterns found in human airways (Fig. 5a). 
Furthermore, Ace2 expression increased over a 2-month time-course of healthy mouse aging in 
both club (p=1.16e-06) and goblet (p=0.01911) cells (Fig. 5a). The proportion of Ace2+Tmprss2+ 
dual-positive cells did not significantly increase with age during this time course (data not shown), 
but the proportion of Ace2+Ctsl+ dual-positive cells significantly increased in club cells during this 
time-course (Fig. 5b). Interestingly, the mice were aged between 2-4 months, a 2-month period 
that is reported to reflect the maturation period from early to mature adults100. Examining bulk 
RNA-Seq profiles of sorted populations of alveolar AT2 cells (SFTPC+), airway basal cells 
(KRT5+), alveolar endothelial cells (CD45-CD31+), alveolar epithelial cells (Epcam+), whole lung 
and whole trachea from a KRT5-CreER/LSL-TdTomato/SFTPC-eGFP transgenic mouse model, 
and across tissues from ENCODE, showed that Ace2, Tmprss2 and Ctsl are expressed in sorted 
AT2 cells, whole trachea and whole lung, as well as in stomach, intestine, kidney and bladder.  
 
In human smokers, statistical modeling uncovered a robust trend of increased ACE2 expression in 
airway epithelial cells, while expression in AT2 cells was reduced (Fig. 3d, Extended Data Fig. 
6). To experimentally confirm these findings, we examined cell profiles from mice exposed daily 
to cigarette smoke for two months, followed by scRNA-seq of whole lungs (Fig. 5c). Epithelial 
specific expression patterns of mouse Ace2 and the Ace2+Tmprss2+ and Ace2+Ctsl+ dual-positive 
cells were largely consistent with the human data (Fig. 5d). Upon smoke exposure, there was a 
significant increase in Ace2+ airway secretory cell numbers, while the fraction of Ace2+ AT2 cells 
was unaltered (Fig. 5e). Moreover, the expression levels of Ace2 were significantly increased in 
airway secretory cells (Fig. 5f), but not in AT2 cells (Fig. 5g). This was in agreement with bulk 
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RNA-seq of mouse lungs exposed to different doses of cigarette smoke101, in which Ace2 levels 
increased in a dose-dependent manner by daily cigarette smoke over 5 months (Fig. 5h). Notably, 
the COVID-19 relevant proteases Tmprss2 and Ctsl were also significantly increased by smoke 
exposure in mice (Fig. 5i,j). Thus, mouse smoking data shows similar trends as observed in 
humans and experimentally confirms the association of ACE2 levels with smoking. 
 
We also compared the patterns between the mouse and human placenta, analyzing Ace2, Tmprss2, 
and Ctsl expression across 100,000 cells from scRNA-seq data during mouse placenta 
development from embryonic days 9.5 to 18 (Shu et al., unpublished). We find Ace2+Tmprss2+ 
dual-positive cells (1.4%) in a large fraction of fetal trophoblasts with strong epithelial signatures. 
Ace2+Tmprss2+ dual-positive cells express signatures of AT2 cells and hepatocytes, and many also 
express Ctsl. Ace2+Ctsl+ dual-positive cells (3.4%) are also present among fibroblasts, stromal 
cells, and fetal trophoblasts in both mice and humans (Fig. 5k, Extended Data Fig. 13). Notably, 
while ACE2+CTSL+ dual-positive fibroblasts and stromal cells in humans are of maternal origin, 
Ace2+Ctsl+ dual-positive fibroblasts and stromal cells are of fetal origin in mice. 
  
Expression patterns of additional proteases that may be relevant to infection 
 
TMPRSS2 has been demonstrated to mediate SARS-CoV-2 infection in vitro37,44, but SARS-CoV-
2 also infects cells in the absence of TMPRSS237. Thus, additional proteases likely play roles in 
proteolytic cleavage events of spike and other viral proteins that underlie entry (fusion) and egress. 
To systematically predict proteases potentially involved in SARS-CoV-2 pathogenesis, we tested 
for co-expression of each of 625 annotated human protease genes102 with ACE2 in the large 
declined donor transplant dataset (“Regev/Rajagopal”) from 10 patients. The analysis recovered 
TMPRSS2 as one of the significantly co-expressed in multiple lung epithelial cell types (Fig. 6a, 
Supplementary Table 11, 12). In addition, multiple members of the proprotein convertase 
subtilisin kexin (PCSK) family were also significantly co-expressed with ACE2 in both proximal 
and distal airway epithelial cells (Fig. 6a,b), including FURIN, PCSK2, PCSK5, PCSK6 and 
PCSK7 in AT2 cells. Proprotein convertases have known roles in coronavirus S-protein 
priming43,103,104. We obtained similar results in an independent dataset of 182,952 cells from 40 
donors (Extended Data Fig. 14a,b, “aggregated lung”).  
 
To further investigate the role of proprotein convertases as candidates for SARS-CoV-2 S-protein 
processing we analyzed the SARS-CoV-2 spike protein sequence. Multiple sequence alignment of 
S-protein sequences of SARS-CoV-2 and other beta-coronaviruses revealed a polybasic insert at 
the S1/S2 junction present only in SARS-CoV-2 spike (Extended Data Fig. 14c). While polybasic 
sites are found in multiple members of betacoronavirus lineages A and C (e.g., MERS-CoV), 
SARS-CoV-2 is the only known member of lineage B harboring a polybasic motif in the S1/S2 
region (Extended Data Fig. 14c). As previously reported, this polybasic sequence corresponds 
well to cleavage motifs of multiple PCSK family proteases (Extended Data Fig. 14d)105–107, and 
has a high probability for its PCSK-mediated cleavage (at amino acid 685) (by ProP and 
PROSPERous108,109) as well as additional sites including the S2’ position (at amino acid 815), 
which would release predicted fusion-mediating peptides (Extended Data Fig. 14e)110.  
 
We next examined PCSKs expression and co-expression with ACE2 across lung cell subsets (Fig. 
6c, Extended Data Fig. 14f). FURIN, PCSK5 and PCSK7 were broadly expressed across multiple 
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lung cell types, and PCSK1 and PCSK2 were largely restricted to neuroendocrine cells, as 
previously reported107, with PCSK2 further detected in 11.2% of AT2 cells (Fig. 6d, Extended 
Data Fig. 14g). In many cell subsets we observed dual expression with ACE2 at fractions 
comparable to or higher than those of ACE2+TMPRSS2+ cells (Fig. 6e, Extended Data Fig. 14h). 
These include AT2 cells (ACE2+TMPRSS2+, ACE2+FURIN+ and ACE2+PCSK2+ at 0.90%, 0.78%, 
and 0.56%, Fig. 6e); multiciliated cells in the proximal airway (ACE2+TMPRSS2+, 
ACE2+FURIN+, ACE2+PCSK7+, and ACE2+PCSK5+ at 0.91%, 0.37%, 1.02%, and 0.91%), and 
basal cells (ACE2+TMPRSS2+, ACE2+FURIN+, and ACE2+PCSK7+ at 0.19%, 0.21%, and 0.74%). 
Co-expression is present across tissues in addition to the lung (Extended Data Fig. 14i,j), 
including the liver, ileum, kidney and nasal airways, with the highest percentages of ACE2+PCSK+ 
dual positive cells in nasal airways (ACE2+PCSK7+ 1.36%, ACE2+FURIN+ 0.67%), bladder 
(ACE2+PCSK5+ 0.45%) and testis (ACE2+PCSK7+ 0.41%).  
 
Because different host proteases may contribute to different stages of the viral life cycle107,111, we 
also examined the prevalence of ACE2+TMPRSS2+PCSK+ triple-positive cells (TPs) in the lung 
dataset. ACE2+TMPRSS2+PCSK7+ were the main triple positive cells in multiciliated (0.75%) and 
secretory cells (0.72%) of proximal airways, and ACE2+TMPRSS2+FURIN+ TPs were the most 
common within AT2 cells (0.36%) (Extended Data Fig. 14k). Finally, when we examined all 
known human proteases for co-expression with ACE2 in major lung epithelial cell types (Fig. 6f), 
we recovered cathepsins (CTSB, CTSC, CTSD, CTSL, CTSS), proteasome subunits (e.g. PSMB2, 
PSMB4, PSMB5), and complement proteases (C1R, C2, CFI) (Fig. 6f, Extended Data Fig. 15), 
the latter also captured in our programs above (Fig. 4).  
 
 
DISCUSSION 
 
We performed integrative analyses of single-cell atlases in the lung and airways and across tissues 
to identify cell types and tissues that have the key molecular machinery required for SARS-CoV-
2 infection. We then examined the relationship between specific cell types and three key covariates 
-- age, sex, and smoking status -- that have been related to disease severity. We further used the 
scale of these integrated atlases to identify gene programs in major epithelial cell subsets that may 
be infected by the virus, and search for other potential accessory proteases. Our hope is that this 
extensive analysis and resource will help with hypothesis generation (and refutation) towards 
better understanding of the molecular and cellular basis of COVID-19 infection, and the 
identification of putative therapeutic avenues.  
 
Our cross-tissue analysis substantially expands on our 45,46,58,112 and others’ 113–115  earlier efforts, 
allowing us to identify cell subsets across diverse tissues that may be implicated in virus 
transmission, pathogenesis, or both. Focusing on pathogenesis, in addition to key subsets in the 
lung, airways and gut, we identified ACE2+ cells that co-express either TMPRSS2 or CTSL in 
diverse organs, many of which have been associated with severe disease. These include epithelial 
cells in the liver, kidney, pancreas, and olfactory epithelium, cardiomyocytes, pericytes and 
fibroblasts in the heart, and oligodendrocytes in the brain. For example, the presence of double 
positive cardiomyocytes and cardiac pericytes and fibroblasts may provide a pathological basis for 
the cardiac abnormalities noted in COVID-19 patients including elevated troponin, a signature of 
cardiomyocyte injury, myocarditis, and sudden cardiac death5. As the co-expression of genes 
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involved in SARS-CoV2 infection are highest in cardiac pericytes in healthy heart, damage to 
vascular beds may trigger troponin release in otherwise normal hearts. Moreover, as myocardial 
ACE expression is increased in patients with existing cardiovascular  diseases (Tucker et al. 
companion manuscript58), SARS-CoV2 infection may result in greater damage to cardiomyocytes, 
and account for greater disease acuity and poorer survival in these patients.  
 
One intriguing clinical observation is that some COVID-19 patients display an array of neurologic 
symptoms116,117,118, reported as seizures and acute necrotizing encephalopathy, similar to that 
previously observed following other infections such as influenza119,120. Neuroinflammation could 
result from direct viral infection of the brain, or a systemic cytokine storm121–123,124–126,121–123. 
Direct viral invasion of SARS-CoV and MERS-CoV is observed in multiple brain regions in 
human patients and mouse models124,125, consistent with widespread ACE2 expression in numerous 
brain cell types. Furthermore, SARS-CoV has been shown to infiltrate the brain via the olfactory 
epithelium–olfactory bulb axis127; olfactory transmission for SARS-CoV-2 has been recently 
proposed128. Other possible transmission routes could be through the infection of 
ACE2+TMPRSS2+ enteric neurons synapsing with vagal afferents, or entry through blood-CNS 
interfaces such as the choroid plexus or meninges121,129–131. Profiling immune cells at these sites 
after infection is an important future step to better understand how the viral response may lead to 
encephalitis. One intriguing possibility is that encephalitis might arise as an autoimmune response 
to myelin antigens expressed by infected cells. Antibodies against peptides of myelin proteins have 
been clinically shown to be associated with autoimmune encephalitis and seizures132–134, and 
myelin peptides are targets of T cells135 in demyelinating inflammatory neurological diseases such 
as acute demyelinating encephalomyelitis, Guillain-Barre Syndrome, and multiple sclerosis135–142. 
Oligodendrocytes, the myelin-producing cells of the CNS, are the main ACE2+TMPRSS2+ cell 
type in the brain, the myelin transcriptional regulator MYRF was enriched in certain 
ACE2+TMPRSS2+ cell types as noted above, and myelin proteins MOG and MBP were co-
expressed in numerous ACE2+ clusters across organs. MYRF and MBP were significantly 
differentially expressed in ACE2+TMPRSS2+ subsets of the lung and gut (Supplementary Table 
10); myelin targeting Th17 cells trained in the gut are able to infiltrate the CNS in a mouse model 
of experimental autoimmune encephalomyelitis143. Taken together, the expression of myelin 
proteins across multiple ACE2+TMPRSS2+ cells may hypothetically contribute to antigen 
presentation and autoimmune response in the context of viral infection. A small number of 
COVID-19 patients were reported to have Guillain-Barre Syndrome144, with a demyelinating 
process in some; this is consistent with observations of Guillain-Barre Syndrome following other 
viral infections such as Zika, influenza, and Epstein-Barr virus139,145,146. Whether anti myelin 
specific immunity can be induced by virus infected cells expressing myelin proteins remains an 
area for future study. 
       
Our meta--analysis of scRNA-seq across studies provided the required statistical power to uncover 
population-level signals at a molecular level and at single-cell resolution. We found that the SARS-
CoV-2 receptor and associated proteases were up-regulated in airway epithelial and AT2 cells with 
age and in males, an association that may shed light on the marked increase in mortality with age. 
Furthermore, ACE2 was up-regulated in airway epithelial cells (basal and multiciliated cells) in 
past or present smokers, but down-regulated in their AT2 cells; we have also confirmed this in an 
experimental system in a mouse model. These contrasting smoking associations show the 
importance of the single-cell resolution, as the down-regulation in AT2 cells will be masked by 
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the airway epithelial signal, leading to loss of association or misinterpretation of seemingly 
consistent ACE2 signals in bulk RNA-Seq147. Importantly, ACE2 is particularly lowly expressed 
in young pediatric samples, also mirrored by lack of chromatin accessibility in the ACE2 locus. 
ACE2 expression is known to be regulated in complex ways across different tissues and may be 
affected by both common therapies (ACEi/ARB) (Tucker et al., companion manuscript58), and 
during infection46. Moreover, both higher ACE2 expression per cell and a higher fraction of ACE2+ 
cells can in principle have implications for infection, but may have conflicting effects on 
pathogenesis, as ACE2 knockout mice show more severe ARDS upon lung injury because of its 
role in the renin-angiotensin pathway, which seems to protect from consequences of lung injury 
and inflammation148 (for potential roles of this pathway on CoV infection (pre-COVID) see the 
review in 149). As SARS-CoV2 binding will lead to internalization and therefore downregulation 
of ACE2 on the cell surface, the protective function of ACE2 via its proteolytic processing of 
Angiotensin-II may be lost. Thus, the smoking mediated downregulation of ACE2 in AT2 cells 
may not protect cells from being infected but rather may increase ARDS due to more severe loss 
of ACE2 from the cell surface upon infection. Other confounders, including ACEi which are not 
available to our meta-analysis may further impact our results. 
  
To the best of our knowledge, this study is the first single-cell meta-analysis (in any setting). To 
perform this meta-analysis, we used a model that included both the tested covariates (age, sex, and 
smoking status), technical covariates (dataset and the number of UMIs per cell), and several 
interaction terms. Including these interaction terms was crucial, as omission resulted in increased 
background variation and reversed effect estimates. Likewise, modeling the smoking status of a 
donor was important to reduce background variation and account for the unbalanced distribution 
of covariates in the dataset. For example, while we have similar numbers of male ascertained 
smokers and non-smokers (21 and 20 donors), there are three times as many female ascertained 
non-smokers as female smokers (27 and 9 donors), which is reflective of this bias in the 
population150. The addition of these terms increases the complexity of the model. Indeed, only one 
dataset (“Seibold”) had sufficient numbers of donors of various ages, sex, and smoking status to 
fit the full model. Thus, performing the meta-analysis was only possible due to the aggregation of 
a large number of healthy single-cell datasets enabled by the HCA Lung Biological Network and 
a community-wide effort. 
 
A limitation of our expression model is that each cell is treated as an independent observation. 
Thus, the significance of association with traits such as sex, age, and smoking status may show 
inflated p-values, especially where the associations are determined from few donors. In this case, 
the variation between cells from a single donor dominates the variation between donors, 
background variation is underestimated and effect significance can be overestimated. Aggregating 
many datasets allows us to counteract this effect, yet p-value inflation may occur in cell types that 
are not as commonly shared across datasets. Our main conclusions are drawn on airway epithelial 
and AT2 cells, which are distributed widely across datasets and are modeled on the basis of many 
donors. Furthermore, we have confirmed significant associations by pseudo-bulk analysis and by 
holding out datasets. This confirmation ensures that associations are consistent when only 
considering donor variation, and we are aware if these associations are dataset dependent (often 
when one dataset is a particularly major source of a given cell type). Models that account for both 
single-cell count distributions, and population structure in the data have the potential to improve 
future meta-analyses across single-cell atlases. 
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Having a cell type annotation with consistent resolution across datasets was instrumental for 
analyzing the association with clinical covariates up to the resolution of basal, secretory, or 
multiciliated cells. These cell type labels still aggregate over considerable diversity, which is the 
subject of ongoing scientific research. Importantly, the labeled subtypes of these cell clusters differ 
between datasets. Thus, in those cases where individual associations depend on a particular dataset 
not being held out, it may be the case that these associations become more robust at a higher level 
of cell type annotation. Future high-resolution cell annotation efforts have the potential to further 
consolidate our single-cell meta-analysis results. 
 
In addition to modeling associations between gene expression and clinical co-variates, we also 
examined whether the proportion of ACE2+TMPRSS2+ cells per sample is associated with age or 
sex. While we can observe a trend of double positive cell proportions increasing with age 
(Extended Data Fig. 3a), the high compositional diversity across samples and studies (Fig. 3a, 
Extended Data Fig. 16), the potential confounders (total counts, dataset), and limited sample 
numbers are prohibitive to modeling these associations. Further metadata that describe the sample 
diversity such as harmonized annotations on anatomical location, sampling methods, and sample 
processing can help to capture this heterogeneity in ACE2+TMPRSS2+ cell proportion models. 
 
The expression of ACE2 and TMPRSS2 in lung, nasal and gut epithelial cells is associated with 
expression programs with many shared features, involving key immunological genes and genes 
related to viral infection, raising many hypotheses for future studies, especially as more patient 
tissue samples are analyzed in the coming months. In the lung, epithelial cells express IL6, IL6R 
and IL6ST, which raises the hypothesis that infection may trigger cytokine expression from these 
cells and contribute to uncontrolled immunological responses. The immune-like programs in these 
cells are further reinforced by the accessibility of STAT and IRF binding sites in scATAC-Seq 
data, consistent with another study from our network showing the role of interferon in regulating 
ACE2 expression in epithelial cells46. Notably, scRNA-Seq analysis of immune cells from 
bronchoalveolar lavage fluid of COVID-19 patients identified high activity of transcription factors 
such as STAT1/2 and IRF1/2/5/7/8/9 in macrophage states increased in severe COVID-19 
patients151.  Other hypotheses for future studies include lysosomal genes in dual positive lung 
secretory and multiciliated cells, which may be consistent with putative “viral entry” cells, and 
RIPK3 expression in the cell programs of airway cells, which opens the hypothesis of necroptosis 
initiating a pro-inflammatory response. Interestingly, we observed relatively high enrichment of 
ACE2 in secretory cell types (mucous cells and AT2 cells). We speculate that viruses may take 
advantage of the rich secretory pathway components in these cells for their efficient dispersal. 
Additionally, SMGs of the airways are recently shown to serve as reservoirs of reserve stem cells 
152,153. Therefore, we also speculate that SMGs similarly may serve as reservoirs for viruses where 
they can escape from muco-ciliary transport and mechanical expulsion associated with severe 
cough in the airway luminal surface. 
 
The gene programs of AT2 cells can also contribute to cross talk with alveolar macrophages. Our 
cell-cell interaction analysis suggests that AT2 cells engage with alveolar macrophages through 
Oncostatin M, CSF, IL1 and complement pathways, suggesting therapeutic hypotheses. The 
complement pathway is particularly intriguing in the context of COVID-19. First, viral protein 
glycosylation is a known trigger for the lectin pathway (LP) of the proteolytic complement 
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cascade, such that in addition to classical complement activation via antibody complexes, other 
coronavirus glycoproteins can be recognized by LP-inducing host collectin proteins154,155. 
Moreover, excessive complement activation resulting in acute lung injury and cytokine storms 
were also implicated in the pathogenesis of SARS156, and complement inhibition using the anti-
C5 antibody eculizumab157 is currently evaluated as anti-inflammatory experimental emergency 
treatment for severe COVID-19 in clinical trials (ClinicalTrials.gov identifier NCT04288713). In 
our analysis, multiple complement pathway proteases (e.g. C1R, C2, CFI) are co-expressed with 
ACE2 across different lung cell subsets (Fig. 6f,g, Extended Data Fig. 15) and complement 
inhibitory factor CD55 and complement protease C3 were preferentially expressed by 
ACE2+TMPRSS2+ DPs within lung tissue, in multiciliated and secretory cells, respectively (Fig. 
4a,c, Supplementary Table 6, Supplementary Tables 7,8). Moreover, cell-cell interaction 
analysis predicted cross-talk between AT2 cells expressing complement proteins C3 and C5 and 
macrophages expressing cognate receptors. AT2 cell expression of negative complement 
regulators CFI and CD55 might represent a strategy for SARS-CoV-2 to at least partially escape 
complement surveillance.  
 
Finally, to explore therapeutic hypotheses related to disruption of viral processing via protease 
inhibition, we explored the expression of other proteases across our integrated atlases. Although a 
multitude of different SARS-CoV-2 features likely account for its high pathogenicity and 
transmissivity, it has been speculated that the PRRAR loop might contribute to increased COVID-
19 severity. Introduction of similar polybasic cleavage sites into avian influenza viruses and human 
coronaviruses was shown to render them more pathogenic, increasing mortality and viral 
spread158,159. One hypothesis is that acquisition of a PCSK cleavage site would expand the number 
of cell types that can be directly infected by SARS-CoV-2. A recent report has started to address 
expression of FURIN in cells expressing SARS-CoV-2 host factors ACE2 or TMPRSS247, and 
FURIN activity is inhibited by Guanylate-binding proteins (GBPs), a group of interferon-
stimulated genes, in order to restrict viral envelope processing160. However, the highly overlapping 
recognition sequence of PCSK family members (Extended Data Fig. 14d) suggests that multiple 
PCSKs in addition to FURIN could mediate cleavage at the S1/S2 PRRAR motif (Extended Data 
Fig. 14e). Our expression analysis confirms that PCSK family members, in particular FURIN, 
PCSK5 and PCSK7, are more broadly expressed than TMPRSS2 across lung cell types (Fig. 6d), 
as well as across tissues (Extended Data Fig. 14i). In the lung, we note the higher proportion of 
ACE2+PCSK7+ basal cells and ACE2+PCSK7/5+ fibroblasts (Fig. 6e, Extended Data Fig. 14h). 
Interestingly, the host interactome of SARS-CoV-2 further suggests interaction of viral proteins 
with PCSK689, which also showed significant ACE2 co-expression in AT2 cells (Fig. 6b, 
Extended Data Fig. 14b). Moreover, because PCSK localization is detected in different 
membrane compartments along the secretory and endocytic pathways107, it is conceivable that 
PCSKs could process SARS-CoV-2 S-proteins at different stages of the viral life cycle. Moreover, 
further analysis is required to assess the extent to which SARS-CoV-2 relies on proteolytic activity 
provided in trans either by neighboring cells or extracellularly localized proteases111. Altogether, 
this could provide SARS-CoV-2 with an immense flexibility in different entry and egress 
pathways. 
 
Taken together, our analyses provide a rich molecular and cellular map as context for the 
transmission, pathogenesis, clinical associations, and therapeutic hypotheses for COVID-19. As 
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new single cell atlases will be generated from COVID-19 tissues and experimental models, they 
will help further advance our understanding of this disease. 
 
 
METHODS 
 
Patient samples 
 
Sample collection underwent IRB review and approval at the institutions where the samples were 
originally collected. “Adipose_Healthy_Manton_unpublished” was collected under  IRB   
2007P002165/1(ORSP-3877).  Tissue samples from breast, esophagus muscularis, esophagus 
mucosa, heart, lung, prostate, skeletal muscle and skin referred to as 
“Tissue_Healthy_Regev_snRNA-seq_unpublished” were collected under ORSP-3635. Samples 
referred to as “Eye_Sanes_unpublished” were collected under Dana Farber / Harvard Cancer 
Center Protocol Number 13-416 and Massachusetts Eye and Ear Protocol Number 18-034H. 
Samples referred to as “Kidney_Healthy_Greka_unpublished” were collected under 
Massachusetts General Hospital IRB number 2011P002692. Samples referred to as 
“Liver_Healthy_Manton_unpublished” were collected under IRB 02-240; ORSP 1702 as well as 
and ORSP-2630 under ORSP-2169. Lung samples from smokers and non-smokers with suffix 
“Regev/Rajagopal_unpublished” were collected under Massachusetts General Hospital IRB 
2012P001079 / (ORSP-3900) under ORSP-3490. Healthy and fibrotic lung samples with suffix 
“Xavier_snRNA-seq_unpublished“ were collected under Massachusetts General Hospital IRB 
number 2003P000555 (CG-5242) under ORSP-3490, Medoff, 2015P000319 (CG-5145) under 
ORSP-3490. Pancreas PDAC samples were collected under Fernandez-del Castillo, 2003P001289 
(CG-4692) under ORSP-3490 Massachusetts General Hospital IRB number Fernandez-del 
Castillo, 2003P001289 (CG-4692) under ORSP-3490. Samples in the dataset “Barbry” were 
derived from a study that was approved by the Comité de Protection des Personnes Sud Est IV 
(approval number: 17/081) and informed written consent was obtained from all participants 
involved. All experiments were performed during 8 months, in accordance with relevant guidelines 
and French and European regulations. No deviations were made from our approved protocol 
named 3Asc (An Atlas of Airways at a single cell level - ClinicalTrials.gov identifier: 
NCT03437122). IPF and COPD lungs in the “Kaminski” dataset were obtained from patients 
undergoing transplant while healthy lungs were from rejected donor lung organs that underwent 
lung transplantation at the Brigham and Women’s Hospital or donor organs provided by the 
National Disease Research Interchange (NDRI).  Patient tissues relating to the dataset “Krasnow” 
were obtained under a protocol approved by Stanford University’s Human Subjects Research 
Compliance Office (IRB 15166) and informed consent was obtained from each patient prior to 
surgery. The study protocol was approved by the Partners Healthcare Institutional Board Review 
(IRB Protocol # 2011P002419). Samples in the dataset “Kropski_Banovich” were collected under 
Vanderbilt IRB # 060165, 171657, and Western IRB#20181836. Ethics approval number 
2018/769-31. “Meyer_b” were collected under CBTM (Cambridge Biorepository for Translational 
Medicine), research ethics approval number: UK NHS REC approval reference number 
15/EE/0152. Samples in the dataset “Linnarsson” are covered by (2018/769-31) approved  by the 
Swedish Ethical Review Authority. Samples in the “Misharin” dataset were collected under 
(STU00056197, STU00201137, and STU00202458) approved by the Northwestern University 
Institutional Review Board. Samples in the “Rawlins” dataset were obtained from terminations of 
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pregnancy from Cambridge University Hospitals NHS Foundation Trust under permission from 
NHS Research Ethical Committee (96/085) and the Joint MRC/Wellcome Trust Human 
Developmental Biology Resource (grant R/R006237/1, www.hdbr.org, HDBR London: REC 
approval 18/LO/0822; HDBR Newcastle: REC approval 18/NE/0290). The studies relating to 
datasets “Schultze” and “Schultze_Falk” were approved by the ethics committees of the University 
of Bonn and University hospital Bonn (local ethics vote 076/16) and the Medizinische Hochschule 
Hannover (local ethics vote 7414/2017). Fifteen human tracheal airway epithelia in the “Schultze” 
dataset were isolated from de-identified donors whose lungs were not suitable for transplantation. 
Lung specimens were obtained from the International Institute for the Advancement of Medicine 
(Edison, NJ) and the Donor Alliance of Colorado. The National Jewish Health Institutional Review 
Board (IRB) approved the research under IRB protocols HS-3209 and HS-2240. Donor lungs 
samples in the “Xu/Whittset” dataset were provided through the federal United Network of Organ 
Sharing via the National Disease Research Interchange (NDRI) and International Institute for 
Advancement of Medicine (IIAM) and entered into the NHLBI LungMAP Biorepository for 
Investigations of Diseases of the Lung (BRINDL) at the University of Rochester Medical Center, 
overseen by the IRB as RSRB00047606. Samples in the “Xu/Whitsett” dataset were provided 
through the federal United Network of Organ Sharing via the National Disease Research 
Interchange (NDRI) and International Institute for Advancement of Medicine (IIAM) and entered 
into the NHLBI LungMAP Biorepository for Investigations of Diseases of the Lung (BRINDL) at 
the University of Rochester Medical Center, overseen by the IRB as RSRB00047606. 
(Supplementary Table 1, 2) 
 
Integrated analysis of published datasets  
 
Publicly available single-cell RNA-seq datasets were downloaded from Gene Expression Omnibus 
(GEO)161. We searched GEO for datasets that met all of the following three criteria: (1) provided 
unnormalized count data; (2) was generated using the 10X Genomics’s Chromium platform162; 
and (3) profiled human samples. These tissue samples spanned a wide range, including primary 
tissues, cultured cell lines, and chemically or genetically perturbed samples. Applying these filters 
increases standardization of sample as the vast majority were prepared using the same 10X 
Chromium instrument and Cell Ranger pipelines. 
 
Datasets comprise of one or more samples (individual gene expression matrices), which often 
correspond to individual experiments or patient samples. In total, this yielded 2,333,199 cells from 
469 samples from 64 distinct datasets (Supplementary Table 1). To allow comparison across 
samples and datasets, we mapped through a common dictionary of gene symbols and excluded 
unrecognized symbols. If a gene from an aggregated master list was not found in a sample, the 
expression was considered to be zero for every cell in that sample. 
 
After all datasets were collected, we quantified the percentage of cells with >0 UMIs for both 
ACE2 and TMPRSS2 or ACE2 and CTSL. For further analyses with broad cell classes, we only 
used datasets with more than 15 double positive cells yielding 252,871 cells from 40 samples. 
 
For integration across datasets, we used two levels of annotations. When possible, every sample 
was annotated with its tissue of origin based on the available metadata from GEO. We excluded 
any sample for which tissue was not specified. For the smaller subset of 252,871 cells we then 
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manually annotated cell clusters with broad cell type classes using marker genes. These clusters 
were generated using the harmony-pytorch Python implementation (version 0.1.1 
(https://github.com/lilab-bcb/harmony-pytorch 163) of the Harmony scRNA-seq integration 
method164 for batch correction and leiden clustering from the Scanpy package (version 1.4.5)165. 
Clusters without clear markers distinguishing types were excluded from further analysis.  
 
Data was processed using Scanpy. Individual datasets were normalized log (UMIs/10,000 +1)  by 
column sum and the log1p function (ln(10,000 * gij + 1) where a gene’s expression profile, g, is 
the result of the UMI count for each gene, i, for cell j, normalized by the sum of all UMI counts 
for cell j. This data normalization step was only used for generating the clusters and cell type 
annotations.  
 
All other statistical tests for the integrated analysis were performed on the cell’s binary 
classification as a double positive or not. For example, for a cell to be considered ACE2+, it has 
>0 ACE2 transcripts. Double positive cells have >0 transcripts for both genes of interest. We used 
Fisher's exact test to test for statistical dependence between the expression of ACE2 and TMPRSS2 
or CTSL and corrected for multiple testing via Benjamini-Hochberg over all tests for each gene 
pair.  
 
Integrated co-expression analysis of high resolution cell annotations across tissues  
 
We compiled a compendium of published and unpublished datasets consisting of 2,433,890 cells 
from 21 tissues and/or organs including adipose, bone marrow, brain, breast, colon, cord blood, 
enteric nervous system, esophagus mucosa, esophagus muscularis, anterior eye, heart, kidney, 
liver, lung, nasal, olfactory epithelium, pancreas, placenta, prostate, skeletal muscle and skin. After 
the harmonization of cell type annotations, ACE2-TMPRSS2 and ACE2-CTSL coexpression were 
assessed using a logistic mixed effect model:  
 𝑌" 	∼ 		𝐴𝐶𝐸2	 + 	 (1	|	𝑠𝑎𝑚𝑝𝑙𝑒_𝑖𝑑)           (1) 
 
where Yi was the binarized expression level of either TMPRSS2 or CTSL, and covariates were 
binarized ACE2 expression in cell i and a sample-level random intercept.  
 
Models were fit separately for each cell type in each dataset. In order to avoid spurious associations 
in cell types with very few ACE2+ cells and due to very low expression of ACE2, we subsampled 
ACE2- cells to the number of ACE2+ cells within each cell type and discarded cell types containing 
fewer than 5 cells expressing either ACE2 or fewer than 5 cells expressing the other gene being 
tested after the subsampling procedure. The significance of the association between ACE2 and 
TMPRSS2/CTSL is controlled for 10% FDR using the statsmodels Python package (version 
0.11.1)166. Data processing was performed using Scanpy Python package (version 1.4.6)165 and 
logistic models were fit using lme4 R package (version 1.1.21)167. 
 
Single-cell ATAC-Seq analysis 
 
Library Generation and Sequencing. Libraries were generated using the 10x Chromium Controller 
and the Chromium Single Cell ATAC Library & Gel Bead Kit (#1000111) according to the 
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manufacturer’s instructions (CG000169-Rev C; CG000168-Rev B) with unpublished 
modifications relating to cell handling and processing. Briefly, human lung derived primary cells 
were processed in 1.5ml DNA LoBind tubes (Eppendorf), washed in PBS via centrifugation at 
400g, 5 min, 4C, lysed for 3 min on ice before washing via centrifugation at 500g, 5 min, 4C. The 
supernatant was discarded and lysed cells were diluted in 1x Diluted Nuclei buffer (10x Genomics) 
before counting using Trypan Blue and a Countess II FL Automated Cell Counter to validate lysis. 
If large cell clumps were observed, a 40µm Flowmi cell strainer was used prior to the tagmentation 
reaction, followed by Gel Bead-In-Emulsions (GEMs) generation and linear PCR as described in 
the protocol. After breaking the GEMs, the barcoded tagmented DNA was purified and further 
amplified to enable sample indexing and enrichment of scATAC-seq libraries. The final libraries 
were quantified using a Qubit dsDNA HS Assay kit (Invitrogen) and a High Sensitivity DNA chip 
run on a Bioanalyzer 2100 system (Agilent). 
  
All libraries were sequenced using Nextseq High Output Cartridge kits and a Nextseq 500 
sequencer (Illumina). 10x scATAC-seq libraries were sequenced paired end (2 x 72 cycles). 
 
Initial data processing and QC. Fastq files were demultiplexed using 10x Genomics CellRanger 
ATAC mkfastq (version 1.1.0). We obtained peak-barcode matrices by aligning reads to GRCh38 
(CR v1.2.0 pre-built reference) using CellRanger ATAC count. Peak-barcode matrices from six 
channels were normalized per sequencing depth and pooled using CellRanger ATAC aggr. 
 
The aggregated, depth-normalized,  filtered dataset was analyzed with Signac (v0.1.6, 
https://github.com/timoast/signac), a Seurat168 extension developed for the analysis of 
scATAC-seq data. All the analyses in Signac were run with a random number generator 
seed set as 1234. Cells that appeared as outliers in QC metrics (peak_region_fragments 
≤ 750 or peak_region_fragments ≥ 20,000 or blacklist_ratio ≥ 0.025 or nucleosome_signal 
≥ 10 or  TSS.enrichment ≤ 2) were excluded from the analysis.  
 
Normalization and dimensionality reduction. The aggregated dataset was processed with Latent 
Semantic Indexing169, i.e. datasets were normalized using term frequency-inverse document 
frequency (TF-IDF), then singular value decomposition (SVD), ran on all binary features, was 
used to embed cells in low-dimensional space. Uniform Manifold Approximation and Projection 
(UMAP)170 was then applied for visualization, using the first 30 dimensions of the SVD space. 
 
Gene activity matrix and differential motif activity analysis. A gene activity matrix was calculated 
as the chromatin accessibility associated with each gene locus (extended to include 2kb upstream 
of the transcription start site, as described in the vignette ‘Analyzing PBMC scATAC-seq’ 
(version: March 13, 2020, https://satijalab.org/signac/articles/pbmc_vignette.html), using as gene 
annotation the genes.gtf file provided together with Cellranger’s atac GRCh38-1.2.0 reference 
genome.  
 
Clusters were annotated using label transfer from matching scRNA samples or by literature / expert 
search of marker “active” (i.e. accessible) genes. Differential motif activity analysis was performed 
using Signac’s implementation of ChromVAR93, with motif position frequency matrices from 
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JASPAR2020171 (http://jaspar.genereg.net/) selecting transcription factors motifs from human 
(species=9606), broadly following the vignette ‘Motif analysis with Signac’ 
(https://satijalab.org/signac/articles/motif_vignette.html). Cells were identified as positive for 
ACE2 and/or TMPRSS2 (i.e. with the loci accessible) if at least one fragment was overlapping with 
the gene locus or 2kb upstream. Differential activity scores between epithelial cells positive for 
ACE2 (with the above-mentioned definition of ‘positive’) and non-expressing ACE2 was 
performed with the FindMarkers function of Seurat (version 3.1.1), using as test ‘LR’ (i.e. logistic 
regression) and as latent variable the number of counts in peak.  
 
Analysis of ENCODE bulk-RNAseq datasets 
The following publically available bulk-RNAseq datasets were obtained from the ENCODE 
database: LID20728; LID20729; LID47030; LID47031; LID47036; LID47037; LID21040; 
LID21041; LID47032; LID47033; LID20870; LID20871; LID20872; LID20873; LID21183; 
LID21184; LID21042; LID21043; LID20920; LID20921; LID20924; LID20925; LID20821; 
LID20822; LID46983; LID46984; LID20819; LID20820; LID21038; LID21039; LID20732; 
LID20733; LID20868; LID20869; LID20922; LID20923, generated by the Gingeras lab172. These 
FASTQ datasets were aligned to the MM9 annotation build using STAR and processed using the 
standard Tuxedo Suite to yield a normalized FPKM matrix. 
 
Immunohistochemistry 
Immunohistochemistry analysis was performed on 4% PFA fixed, OCT embedded tissue sections 
from human explant donors. Briefly, cells were permeabilized with 5% Triton-X in PBS. Slides 
were either not treated with antigen retrieval or antigen retrieval was performed with the Tris-
Citrate buffer as needed (Supplementary Table 4). Slides were incubated overnight with primary 
antibodies at indicated concentrations (Supplementary Table 4) in donkey serum with 5% Triton-
X in PBS. Slides were treated with Alexa-Fluor secondary antibodies mixed with DAPI at 1:500 
concentration in donkey serum with 5% Triton-X in PBS for 1 hour at room temperature. Slides 
were mounted and imaged on a confocal microscope.  
 
Proximity ligation in situ hybridization (PLISH) 
Proximity ligation in situ hybridization (PLISH) was performed as described previously173. 
Briefly, frozen human trachea and distal lung sections were fixed with 4.0% paraformaldehyde for 
20 min, treated with protease (20 µg/mL proteinase K for lung or Pepsin for trachea for 9 min) at 
37°C, and dehydrated with up-series of ethanol. The sections were incubated with gene-specific 
oligos (Supplementary Table 11) in hybridization buffer (1 M sodium trichloroacetate, 50 mM 
Tris [pH 7.4], 5 mM EDTA, 0.2 mg/mL heparin) for 2 h at 37°C. Common bridge and circle probes 
were added to the section and incubated for 1 h followed by T4 ligase reaction for 2 h. Rolling 
circle amplification was performed by using phi29 polymerase (#30221, Lucigen) for 12 hours at 
37°C. Fluorophore-conjugated detection probe was applied and incubated for 30 min at 37°C 
followed by mounting in medium containing DAPI. 
Integrated analysis for association of ACE2 and TMPRSS2 expression with age, sex or 
smoking status in nasal, airways and lung cells 
To assess the association of age, sex, and smoking status with the expression of ACE2, TMPRSS2, 
and CTSL, we aggregated 22 scRNA-seq datasets of healthy human nasal and lung cells, as well 
as fetal samples. Aggregation of these datasets was enabled by harmonizing the cell type labels of 
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individual datasets within Scanpy165 (version 1.4.5.1). We harmonized annotations together with 
data contributors using a preliminary ontology generated on the basis of 5 published datasets63–
66,174 with 3 levels of annotations (level 1 - lowest resolution; Supplementary Table 2). We further 
harmonized metadata by collapsing the smoking covariate into “has smoked” and “has never 
smoked” and by taking mean ages where only age ranges were given. This endeavor produced a 
dataset of 1,176,683 cells in 282 samples from 164 donors (Supplementary Data D3). We divided 
the data into fetal (136,742 cells, 41 samples, 32 donors), adult nasal (32,881 cells, 12 samples, 12 
donors), and adult lung (1,007,060 cells, 229 samples, 127 donors) datasets based on metadata 
provided. 
 
To get an overview of sample diversity, we clustered the samples using the proportion of cells in 
level 2 cell types as features. Clustering was performed using louvain clustering (resolution 0.3; 
louvain package version 0.6.1) on a knn-graph (k=15) computed on Euclidean distances over the 
top 5 principal components of the cell type proportion data within Scanpy. This produced five 
clusters. Sample cluster labels were assigned based on metadata for anatomical location that was 
obtained from the published datasets and via input from the data generators. 
 
Within adult datasets we modeled the association of age, sex, and smoking status with gene 
expression for ACE2, TMPRSS2, and CTSL using a generalized linear model with the log total 
counts per cell as offset and Poisson noise as implemented in statsmodels166 (version 0.11.1) and 
using a Wald test from Diffxpy (www.github.com/theislab/diffxpy; version 0.7.3, batchglm 
version 0.7.4). Specifically we used the model: 
 𝑌"5 ∼ 𝑎𝑔𝑒	 + 	𝑠𝑒𝑥	 + 	𝑎𝑔𝑒: 𝑠𝑒𝑥	 + 	𝑠𝑚𝑜𝑘𝑖𝑛𝑔	 + 	𝑠𝑒𝑥: 𝑠𝑚𝑜𝑘𝑖𝑛𝑔	 + 	𝑎𝑔𝑒: 𝑠𝑚𝑜𝑘𝑖𝑛𝑔	 + 	𝑑𝑎𝑡𝑎𝑠𝑒𝑡      
(2) 
 
Here, 𝑌"5 denotes the raw count expression of gene i in cell j and age:sex, sex:smoking, and 
age:smoking are interaction terms of the three modeled covariates. These terms model whether 
there is a difference in the smoking effect in men and women, and likewise whether the age effect 
is different for smokers and non-smokers. While we model these interaction terms, we only tested 
age, sex, and smoking effects individually to reduce the multiple testing burden. We included the 
dataset term to model the batch effects between the diverse datasets we obtained, and the log total 
counts per cell was used as an offset. Here, the total counts were scaled to have a mean of 1 across 
all cells before the log was taken. In order to fit this model we pruned the data to contain only 
datasets that have at least 2 donors and for which smoking status metadata was provided. This 
resulted in a dataset of 761,693 cells and 165 samples from 77 donors for adult lung data. Only a 
single dataset remained for adult nasal data after this filtering on which the model could not be fit. 
To obtain cell-type specific associations the above model was fit within each cell type for all cell 
types with at least 1,000 cells. We performed Wald tests over the age and sex covariates 
independently and corrected for multiple testing via Benjamini-Hochberg over all tests within a 
cell type. 
 
As metadata on smoking status was only available for a subset of the data, we also fitted a simpler 
model on a larger dataset to confirm sex and age associations. The simplified model: 
 𝑌"5 ∼ 𝑎𝑔𝑒	 + 	𝑠𝑒𝑥	 + 	𝑎𝑔𝑒: 𝑠𝑒𝑥	 + 	𝑑𝑎𝑡𝑎𝑠𝑒𝑡            (3) 
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was fit on 986,342 cells in 225 samples from 125 donors of adult lung data. Again, log total counts 
(scaled) was used as an offset. 
 
The above models treat cells as independent observations and thus model cellular and donor 
variation jointly. As donor variation tends to be larger than single-cell variation, when most cells 
come from few donors (either there are few donors, or few donors contribute most of the cells), 
this can lead to an inflation of p-values. To counteract this effect, we verified that significant 
associations are consistent when modeling only donor variation via pseudo-bulk analysis, and we 
tested whether effects are dependent on few donors by holding out datasets. 
 
Pseudo-bulk data was generated by computing the mean for each gene expression value and nUMI 
covariate for cells in the same cell type and donor. After filtering as described above, models (2) 
and (3) were fit to the data. In contrast to the single-cell model, pseudo-bulk analysis 
underestimates certainty in modeled effects as uncertainty in the pseudo-bulk means are not taken 
into account. Thus, we used only effect directions from pseudo-bulk analysis to validate single-
cell associations. We regarded only those associations as significant, where the FDR-corrected p-
value in the single-cell model is below 0.05, and the sign of the estimated effect is consistent in 
both the single-cell and the pseudo-bulk analysis. 
 
We further separated significant associations into robust trends and indications depending on the 
holdout analysis. A significant association was regarded as a robust trend if the effect direction is 
consistent when holding out any dataset when fitting the model irrespective of p-value. In the case 
that holding out one dataset caused the maximum likelihood estimate of the coefficient to be 
reversed, we denote this as the effect no longer being present, which characterized the association 
as an indication. 
 
Identification of gene programs using feature importances for a random forest trained to 
classify ACE2+TMPRSS2+ vs ACE2-TMPRSS2- cells 
 
For each of the lung, nasal, and gut datasets, we labeled the cells with non-zero counts for both 
ACE2 and TMPRSS2 as dual-positive cells (DPs), and the cells with zero counts for both ACE2 
and TMPRSS2 as dual-negative cells (DNs). Within each tissue, we identified cell types with 
greater than 10 DPs, and for each of these cell types, we selected the genes with increased 
expression (log fold change greater than 0) in DPs vs DNs (so that we focus on important 
”positive” features). We trained a classifier with 75:25 train:test split to classify the DPs from DNs 
within each of these cell types using the sklearn (version 0.21.3)175 RandomForestClassifier 
function with the following parameters: n_estimators set to 100, the criterion as gini, and the 
class_weight parameter set to balanced_subsample. We first trained individual classifiers 
separately for each of the cell types, and pooled genes with positive feature importance values 
(using the feature_importance176 field in the trained RandomForestClassifier object) to train a final 
DP vs DN classifier across each tissue. We used the top 500 genes, as ranked by their feature 
importance scores, to define the signature for the gene expression program of DPs for the tissue. 
This procedure was carried out in lung, nasal, and gut datasets, yielding tissue-specific signatures 
for gene expression programs of DPs from each tissue. 
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For visualization purposes only, we generated network diagrams using the networkx (version 
2.2)177 tool with the ForceAtlas2 graph layout algorithm178. We scored genes that appeared in 
signatures for multiple tissues by their aggregated feature importance (using a plotting heuristic 
that used the sum of importance ranks for genes in individual tissues and by assigning a large 
valued rank (10000) to a gene that did not appear in a particular tissue) and selected the top 10 
genes that were shared by each pair of tissues or shared by all tissues along with additional genes 
that included the ones unique to each tissue’s signature to plot in the network visualization. The 
GO terms enriched in the gene expression programs shared by DPs across tissues were found using 
gprofiler (version 1.0.0)179 using the scanpy.queries.enrich tool.  
 
This analysis was performed in two ways: on the original data, as well as after accounting for 
differences in distribution of the number of UMIs (nUMI) per cell between DPs and DNs. This 
was done by binning the nUMI distribution in the DPs for each tissue into a 100 bins and then 
randomly sampling from the nUMI distribution for the DNs in each bin to match the distribution 
of the DPs in that bin. The nUMI distributions before and after the matching are shown in 
Extended Data Fig. 10b.    
 
Identification of gene programs enriched in DP vs. DN cells using regression  
 
In parallel, we used a regression framework to recover gene modules enriched in DP vs. DN cells 
(Fig. 4c,d, Extended Data Fig. 11a,b) in the nasal, lung, and gut datasets. We first restricted our 
analysis to cell subsets derived from at least two donor individuals that each contained a mixture 
of DN and DP cells (Nawijn Nasal: multiciliated, Goblet; Regev/Rajagopal Lung: AT1, AT2, 
Basal, multiciliated, Secretory; Aggregated Lung: AT2, multiciliated, Secretory; Regev/Xavier 
Colon: BEST4+ Enterocytes, Cycling TA (Transit Amplifying), Enterocytes, Immature 
Enterocytes 2, TA-2). For each of these cell subsets, we then used MAST (version 1.8.2)180 to fit 
the following regression model to every gene with cells as observations: 
  𝑌" ∼ 𝑋	 +	(1|𝑆), 
 
where Yi is the expression level of gene i in cells, measured in units of log2(TP10K+1), X is the 
binary co-expression state of each cell (i.e. DP vs. DN), and S is the donor that each cell was 
isolated from. To control for donor-specific effects (i.e. batch effects), we used a mixed model 
with a random intercept that varies for each donor. To fit this model, we subsampled cells from 
DP and DN groups to ensure that both the donor distribution and the cell complexity (i.e. the 
number of genes per cell) were evenly matched between the two groups, as follows. First, for each 
subset, we restricted our analysis to donors containing at least two DN and two DP cells. Using 
these samples, we partitioned the cells into 10 equally-sized bins based on cell complexity and 
subsampled DN cells from each bin to match the cell complexity distribution of the DP cells. 
Finally, we fit the mixed model (above), controlling for both donor and cell complexity. 
 
To build gene modules for DP cells, we prioritized genes by requiring that they be expressed in at 
least 10% of DP cells, and to have a model coefficient greater than 0 with an FDR-adjusted p-
value less than 0.05 (for the combined coefficient in the hurdle model). After this filtering step, 
genes were ranked by their model coefficient (i.e. estimated effect size). The top 12 genes were 
selected for network visualization within each cell type (Fig. 4c,d, Extended Data Fig. 11a,b). In 
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three cases (gut Cycling TA, TA-2 and BEST4+ cells), RP11-* antisense genes were flagged and 
excluded from visualizations. To visualize overlap across each network, we indicated whether each 
gene was among the top 250 genes from each of the other cell types. Putative drug targets were 
identified by querying the Drugbank database88. Gene set enrichment analysis was performed 
using the R package EnrichR (version 1.0)181, selecting the top 25 genes from each cell type for 
the pan-tissue analysis (“All” category; Fig. 4e), and the top 50 genes from each cell type for the 
tissue-specific analyses (“Gut”, “Nasal”, and “Lung” categories; Fig. 4e). We note a few 
caveats/challenges/limitations that may influence our results, including non uniform sampling 
across donors; variation in cell compositions across regions (e.g., distal lung vs carina), and 
additional cellular heterogeneity that the current level of broad subset annotation may not have 
been captured.  
 
Cell-Cell interaction analysis 
 
CellphoneDB96 v.2.0.0 was run with default parameters on the 10 human lung samples of the 
Regev/Rajagopal dataset, analyzing the cells from each dissected region separately. For each 
sample (patient/location combination), for each cell type we distinguished double positive cells 
(ACE2 > 0 and TMPRSS2 > 0) from all others. Only interactions highlighted as significant, i.e. 
present in the “significant means” output from CellphoneDB were considered.  
 
 
Co-expression patterns of additional proteases and IL6/IL6R/IL6ST 
 
ACE2-protease co-expression (Figure 6, Extended Data Fig. 14) and ACE2-IL6/IL6R/IL6ST co-
expression (Extended Data Fig. 12) were tested via the logistic mixed-effects model described in 
“Integrated co-expression analysis of high resolution cell annotations across tissues” (Equation 1, 
above). 
 
Code availability 
 
Data and an interactive analysis examining the co-expression of genes across datasets can be 
accessed via the open-source data platform, Terra at https://app.terra.bio/#workspaces/kco-
incubator/COVID-19_cross_tissue_analysis. 
 
Data availability 
 
Interactive visualization and download of gene expression data can be accessed on the Single Cell 
Portal at https://singlecell.broadinstitute.org/single_cell?scpbr=hca-covid-19-integrated-analysis 
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FIGURE LEGENDS 
 
Figure 1. A cross-tissue survey of ACE2+TMPRSS2+ cells shows enrichment in cells at 
reported sites of disease transmission or pathogenesis. 
(a,b) Dual positive cells are more prevalent in epithelial organs and cells. (a) Proportion of 
ACE2+TMPRSS2+ cells (y axis) per dataset (dots) from 21 tissues and organs (rows). (b) 
Proportion of ACE2+TMPRSS2+ cells (y axis) within cell clusters (dots) annotated by broad cell-
type categories (rows) within each of the top 7 enriched datasets (color legend, inset).  (c,d) 
Significant co-expression of ACE2+TMPRSS2+  or ACE2+CTSL+  highlights cells from tissues 
implicated in transmission or pathogenesis. Significance of co-expression (dot size -
log10(adjusted P-value), Methods; red border: FDR<0.1) of ACE2+TMPRSS2+ (c) or 
ACE2+CTSL+ (d) and effect size (dot color, color bar) for finely annotated cell classes (columns) 
from diverse tissues (rows). Only tissues and cells in at least one significant co-expression 
relationship are shown (Methods). (e-i) In situ validation of dual positive cells in the lung, airways, 
and submucosal gland. (e-g) PLISH and immunostaining in human adult lung alveoli for (e) ACE2 
(white), TMPRSS2 (green) and CTSL (red), (f) ACE2 (white), TMPRSS2 (green) and HTII-280 
(red), (g) ACE2 (red) and Pro-SFTPC (green). (h) PLISH and immunostaining in human large 
airway submucosal glands. ACE2 (red), ACTA2 (green) and DAPI (blue). (i) PLISH in human 
adult large airway. ACE2 (green) and DAPI (blue). 
  
Figure 2. Open chromatin at the ACE2 and TMPRSS2 loci in AT2, ciliated and secretory 
cells in the lung and airways 
(a,c) Single-cell ATAC-seq of lung samples from primary carina (1C) and subpleural parenchyme 
(RPL) (n=1 patient, k=3 samples, 3,366 cells from 1C, 8,340 cells from RPL). Uniform Manifold 
Approximation and Projection (UMAP) embedding of scATAC-seq profiles (dots) colored by (a, 
left) cell types, (a, right) cells with at least 1 fragment (indicating accessibility, open chromatin) 
mapping to the ACE2 gene locus (defined as -2kb upstream the Transcription Start Site to 
Transcription End Site), or by sample location (c). Grey shaded area: epithelial cell types. (b) 
Inferred gene activity of ACE2, TMPRSS2, CTSL across cell types. Log normalized mean 
“scATAC activity score” (quantified from accessibility, open chromatin) (dot color) and 
proportion of cells with active scores (dot size) for ACE2, TMPRSS2, and CTSL (columns) across 
different cell types (rows) from the primary carina (1C) and subpleural parenchyme (RPL). (d) 
Some AT2, ciliated and secretory cells have accessible chromatin at both ACE2 and TMPRSS2 
loci. Proportion of cells (x axis) in each cell type (y axis) with accessible chromatin (at least 1 
fragment) at both the ACE2 and TMPRSS2 loci (defined as -2kb upstream of the Transcription 
Start Site to Transcription End Site). 
Figure 3.  ACE2, TMPRSS2, and CTSL expression in AT2 cells increases with age and 
smoking status, and in men 
(a) Samples in the aggregated lung and airway dataset partition to several classes by their cell 
composition. Percentage of cells (y axis) by level 2 cell annotations (Annotations with a preceding 
“1” indicate coarse annotations) across samples (x axis). The 282 samples are ordered by sample 
composition clusters. (b) Schematic of key lung and airway cell types highlighted in the study. (c) 
Statistical model. Model fitted to the data to assess sex, age, and smoking status associations with 
expression of the three genes. Yi,j denotes gene counts and nUMI denotes the total UMI counts per 
cell. (d) Age, sex, and smoking status associations with expression of ACE2 (blue), TMPRSS2 
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(orange), and CTSL (green) in epithelial cells. Effect size (x axis) of the association, in log fold 
change (sex, smoking status) or slope of log expression with age. Colored bars:  associations with 
an FDR-corrected p-value<0.05, where pseudo-bulk analysis shows a consistent effect direction. 
Error bars: standard errors around coefficient estimates. (e) Distribution of ACE2 and TMPRSS2 
expression across level 3 lung cell types. Red shading indicates the main cell types that express 
ACE2 and TMPRSS2. (f) Hold out analysis shows the robustness of associations to holding out a 
dataset. The values show the number of held-out datasets that result in loss of association between 
a given covariate (rows) and ACE2, TMPRSS2, or CTSL expression in a given cell type (columns). 
Robust trends are determined by significant effects that are robust to holding out any dataset (0 
values). (g) Low expression in pediatric samples. Mean expression level (log CPM, y axis) of 
ACE2 (blue), TMPRSS2 (orange), and CTSL (green) across age bins (x axis) in AT2 (left) and 
ciliated (right) cells. Pediatric samples: 0-10 years. Samples from past or current smokers were 
removed from this plot to avoid smoking confounders. Error bars are omitted due to y-axis 
limitations. They are typically 10-fold the mean value (Supplementary Table 5). Multiciliated and 
AT2 cells are shown as these cell types are present in fetal data, and show significant age 
associations with ACE2 expression. 
 
Figure 4: Tissue and cell-type-specific gene modules in ACE2+TMPRSS2+ cells highlight 
immune and inflammatory features 
  
(a,b) Tissue programs of ACE2+TMPRSS2+ cells in lung, gut, and nasal samples. (a) Selected 
tissue program genes. Node: gene; Edge: program membership. Genes are selected heuristically 
for visualization (Methods).  (b) Enrichment (-log10(adj P-value), x axis) of KEGG pathway gene 
sets (y axis) in the full tissue programs. (c-e) Cell programs of ACE2+TMPRSS2+ cells. (c,d) Top 
12 genes from each cell program recovered for different lung (c) or (d) nasal epithelial cell-type 
(nodes, colors). Colored concentric circles: overlap with a gene in the top 250 significant genes in 
other cell types. ACE2 and TMPRSS2 are included even if not among the top 12. (e) Enrichment 
(-log10(adj P-value), x axis) of KEGG disease and non-disease pathway gene sets in either highly 
significant genes across all tissues (top) or in specific tissues (lung, nose, bottom). (f) Motif activity 
in immune TFs in ACE2+ cells. Significance (-log10(adjusted p-value), x axis) of the top 10 
differential “motif activity scores” (Methods) between epithelial ACE2+ cells or ACE2- cells (y 
axis). (Epithelial cells are: AT1, AT2, secretory, ciliated, ionocytes, and neuroendocrine cells, 
highlighted in the gray shaded area in Fig. 2c). (n=2 locations: primary carina and lung lobes, n=3 
samples per location, n=1 patient). Motifs are extracted from the JASPAR2020 database, motif 
code is shown in each row. Dashed line: threshold for significance (adjusted p-value of 0.05). 
Figure 5: Ace2, Tmprss2 and Ctsl2 expression in similar cell types and follows similar 
patterns with age and smoking.  (a) Gradual increase in Ace2 expression by airway epithelial 
cell type with age. Mean expression (y axis) of Ace2 in different airway epithelial cells (x axis) of 
mice of three consecutive ages (color legend, upper right). Shown are replicate mice (dots), mean 
(bar), and error bars (standard error of the mean (SEM)). (b) Increase in proportion of Ace2+Ctsl+ 
goblet and club cells with age. Percent of Ace2+Ctsl+ cells (x axis) in different airway epithelial cell 
types (y axis) of mice of three consecutive ages (color legend, upper right). Shown are replicate 
mice (dots), mean (bar), and error bars (SEM). (c-j) Increase in Ace2 expression in secretory cells 
with smoking. Mice were daily exposed to cigarette smoke or filtered air as control for two months 
after which cells from whole lung suspensions were analyzed by scRNA-seq (Drop-Seq). (c,d) 
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UMAP of scRNA-seq profiles (dots) colored by experimental group (c) or by Ace2+ cells and 
indicated double positive cells (d). Alveolar epithelial cells (AT1 and AT2) and airway epithelial 
secretory and ciliated cells are marked. (e) The relative frequency of Ace2+ cells is increased by 
smoking in airway secretory cells but not AT2 cells. Relative proportion (y axis) of Ace2+ (red) and 
Ace2- (grey) cells in smoking and control mice of different cell types (x axis). (f, g) Expression of 
Ace2 is increased in airway secretory cells, but not in AT2 cells. Distribution of Ace2 expression 
(y axis) in secretory (f) and AT2 (g) cells from control and smoking mice (x axis). (h-j) Re-analysis 
of published bulk mRNA-Seq101 of lungs exposed to different daily doses of cigarette smoke show 
increased expression of (h) Ace2, (i) Tmprss2, and (j) Ctsl after five months of chronic exposure. 
(k) Expression in placenta. UMAP plots showing expression of Ace2, Tmprss2 and Ctsl in single 
and double positive cells from embryonic days 9.5 to 18 (left) and embryonic day 14.5 (right) of 
mouse placenta development 
Figure 6. ACE2-protease co-expression and SARS-CoV-2 S-protein cleavage sites suggest a 
possible role for additional proteases in infection. 
(a) Multiple proteases are co-expressed with ACE2 in human lung scRNA-seq. Scatter plot of 
significance (y axis, -log10(adjusted P value)) and effect size (x axis) of co-expression of each 
protease gene (dot) with ACE within each indicated epithelial cell type (color). Dashed line: 
significance threshold. TMPRSS2 and PCSKs that significantly co-expressed with ACE2 are 
marked. (b) ACE2-protease co-expression with PCSKs, TMPRSS2 and CTSL across lung cell 
types. Significance (dot size, -log10(adjusted P value)) and effect size (color) for co-expression of 
ACE2 with selected proteases (columns) across cell types (rows).  (c,d) Multiple proteases are 
expressed across lung cell types. (c) Distribution of expression (y axis) for ACE2, PCSKs and 
TMPRSS2 across lung cell types (x axis). White dot: median expression. (d) Proportion of cells (y 
axis) expressing ACE2, PCSK family or TMPRSS2 across lung cell types (x axis), ordered by 
compartment. (e) ACE2+PCSK+ dual positive cells across lung cell types. Fraction (y axis) of 
different ACE2+PCSK+ or ACE2+TMPRSS2+ dual positive cells across lung cell types (x axis). 
Dots: different individuals, line: median. (f) ACE2-protease co-expression analysis for the 20 most 
significant human proteases in AT2 cells. Significance (dot size, -log10(adjusted P value)) and 
effect size (color) for co-expression of ACE2 with different proteases (columns) across cell types 
(rows). (g) Additional protease expression in ACE2+TMPRSS2+ dual positive cells. Significance 
(y axis) and fold change (x axis) of differential expression for each human protease between 
ACE2+TMPRSS2+ dual positive vs dual negative cells within each indicated epithelial cell types 
(color). The top 20 most significantly differentially expressed proteases within AT2 cells and 
PCSKs across all epithelial cell types are highlighted. 
  
Extended Data Figures 
 
Extended Data Figure 1.  A cross-tissue survey of ACE2+TMPRSS2+ cells in published single-
cell datasets. 
(a) Odds ratio (x axis) of ACE2+TMPRSS2+ co-expression in single-cell datasets (dots) from 
different tissues (y axis). (b) Significance (-log10(p-value), x axis) of co-expression of 
ACE2+TMPRSS2+ in single-cell datasets (dots) from different tissues (y axis). (c,d) Proportion (x 
axis) of ACE2+ cells per dataset (c) and TMPRSS2+ cells per dataset (d) across different tissues (y 
axis). 
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Extended Data Figure 2.  A cross-tissue survey of ACE2+CTSL+ cells in published single-cell 
datasets. 
(a) Proportion (x axis) of ACE2+CTSL+ cells per dataset (dots) across different tissues (y axis). (b) 
Proportion (x axis) of ACE2+CTSL+ cells within clusters annotated by broad cell-type categories 
(dots) in each of the top 7 enriched datasets (y axis; color legend, inset). (c) Odds ratio (x axis) of 
ACE2+CTSL+ co-expression in single-cell datasets (dots) from different tissues (y axis). (d) 
Significance (-log10(p-value), x axis) of co-expression of ACE2 and CTSL  in single-cell datasets 
(dots) from different tissues (y axis). (e) Proportion (x axis) of CTSL+ cells per dataset across 
different tissues (y axis). 
  
Extended Data Figure 3. Cellular composition and fraction of ACE2+TMPRSS2+ cells across 
the integrated lung dataset 
(a) Percentage of ACE2+TMPRSS2+ (double positive - DP) cells across samples with sample 
composition. Top:  Percentage ACE2+TMPRSS2+ cells in each sample, from each level 2 cell type 
in which DP cells are found. Bottom: Sample composition. All level 2 cell type annotations where 
no DP cells are found are summarized as “Other” for ease of visualization. Samples are ordered 
by age with 31-week pre-term births and 39-week full-term births both set to age 0. (b) Zoom in 
on fetal and pediatric samples of plot (a). All level 2 cell types without DP cells in fetal and 
pediatric samples are labeled as “Other”. Samples are ordered and labeled by age. Fetal samples 
are partitioned into first and second trimester (TM) and pediatric samples are divided into 31-week 
pre-term births, 39-week full term births, 3 month, 3 year, and 10 year old children. 
  
Extended Data Figure 4. ACE2 expression across tissues and celltypes. 
Shown are fractions of ACE2 expressing cells (dot size) and mean ACE2 expression level in 
expressing cells (dot color) across datasets (rows) and cell types (columns). 
  
Extended Data Figure 5. ACE2, TMPRSS2, CTSL Immunofluorescence and RNA profiling 
(a) Immunostaining in human adult lung alveoli. TMPRSS2 (red), HTII-280 (green) and AGER 
(white). Blue shows DAPI in nuclei.  (b) Mean expression (y axis, FPKM, from bulk RNA-seq) 
of ACE2, CTSL, TMPRSS2 in sorted cells from 3 different human explant donors using the 
following markers:  large and small airway basal cells (NGFR+), AT2 cells (HT-II 280+) and 
alveolar organoids (HT-II 280+). (c) Human adult lung: alveolar section stained with ACE2 
(green) and Pro-SFTPC (red) antibodies and DAPI (blue). (d) Lung from infant donor: alveolar 
section stained with ACE2 (green) and Pro-SFTPC (red) antibodies and DAPI (blue). (e) 
Expression in the submucosal gland. Mean expression (color) and proportion of expressing cells 
(dot size) of ACE2, TMPRSS2 and CTSL in key cell types (rows), from scRNA-seq of human large 
airway submucosal glands. 
  
Extended Data Figure 6. Age, sex, and smoking status associations with expression of ACE2, 
TMPRSS2, and CTSL across level 2 cell type annotations. 
Effect size (y axis) of association as log fold changes (sex, smoking status) and slope of log 
expression with age. Bars that are colored in indicate associations with an FDR-corrected p-value 
of < 0.05 where the pseudo-bulk analysis shows a consistent effect direction. Error bars represent 
model uncertainties. 
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Extended Data Figure 7. Age, sex, and smoking status associations with expression of ACE2, 
TMPRSS2, and CTSL across level 3 cell type annotations. 
Effect size (y axis) of the association as log fold changes (sex, smoking status) and slope of log 
expression with age. Bars that are colored in indicate associations with an FDR-corrected p-value 
of < 0.05 where the pseudo-bulk analysis shows a consistent effect direction. Error bars represent 
model uncertainties. 
  
Extended Data Figure 8. Age and sex associations with expression of ACE2, TMPRSS2, and 
CTSL in level 3 and level 2 cell type annotations on the full, non-fetal, lung data 
Effect size (y axis) of the association as log fold changes (sex, smoking status) and slope of log 
expression with age. Bars that are colored in indicate associations with an FDR-corrected p-value 
of < 0.05 where the pseudo-bulk analysis shows a consistent effect direction. Error bars represent 
model uncertainties. (a) Level 3 and (b) Level 2 cell type annotations. 
 
Extended Data Figure 9.  Chromatin accessibility at the ACE2, TMPRSS and CTSL loci 
across lung cells in early life 
(a) Schematic: single-cell chromatin accessibility by transposome hypersensitive sites sequencing 
(THS-Seq) from human pediatric samples (full gestation, no known lung disease) collected at day 
1 of life, 14 months, 3 years, and 9 years (n=1 at each time point). (b) Accessibility (dot color log 
normalized gene activity scores), and % of cells with accessible loci (dot size) for the ACE2, 
TMPRSS, and CTSL loci (columns) across different cell types (rows) in scTHS-Seq with all time 
points aggregated. (c) Accessibility (dot color log normalized gene activity scores), and % of cells 
with accessible loci (dot size) of ACE2, TMPRSS and CTSL in AT1--AT2 cells in scTHS-Seq at 
day 1 of life, 14 months, 3 years, and 9 years (rows). (d) Number of ACE2+CTSL+ and 
ACE2+TMPRSS2+ cells per time point.  
 
Extended Data Fig. 10.  Tissue programs for dual positive cells 
(a) Selected tissue program genes. Node: gene; Edge: program membership. Genes are selected 
heuristically for visualization, derived from the positive feature importance values of a random 
forest classifier without nUMI distribution matching (Methods).). (b) Stratified subsampling to 
match nUMI distributions. (c,d) Enrichment (-log10(adj P-value), x axis) of GO Biological 
Process (c) and KEGG pathway (d) gene sets (y axis) in the full tissue programs without nUMI 
distribution matching. 
 
Extended Data Fig. 11.  Cell programs for dual positive cells 
(a,b) Top 12 genes from each cell program recovered for different lung (a) or gut (b) epithelial 
cell-type (nodes, colors). Colored concentric circles: overlap with a gene in the top 250 significant 
genes in other cell types. ACE2 and TMPRSS2 are included even if not among the top 12. (c) 
Comparison of signature scores of cell programs between DP and DN cells for each cell type 
stratified by gene complexity bin. Cells were partitioned into 10 gene complexity bins for every 
cell type. (d,e) IL6 and its receptor’s expression in specific cell types in lung and heart. (d) 
Significance (dot size) and fold change (dot color) of differential expression between DP and DN 
cells within different types (rows) for IL6 and its receptors IL6R and IL6ST (columns) across 
tissues. (e) Top: Significance (dot size) and fold change (dot color) of differential expression 
between DP and DN cells within different cell types in the heart (rows)for IL6 and its receptors 
IL6R and IL6ST (columns). Bottom: Significance (dot size) and effect size (dot color) from a mixed 
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effects model of co-expression of IL6, IL6R, or IL6ST (columns) coexpression with ACE2. (f)  
Distribution of number of counts in peaks (y axis) in ACE2+ epithelial cells (having at least 1 
fragment in the ACE2 gene locus) and ACE2- cells. 
  
Extended Data Figure 12. Co-expression of ACE2 and IL6,IL6R,IL6ST. 
Co-expression of ACE2 and IL6,IL6R,IL6ST in select single-cell datasets. P-values and 
significance (FDR 10%) derived from the logistic mixed-effects model. 
 
Extended Data Figure 13.  Expression of Ace2, Tmprss2 and Ctsl in mouse placenta. 
UMAP embedding (as in Fig. 5k) of scRNA-seq profiles of placenta cells collected at E.14.5 (top) 
or along a time course (bottom), colored by expression level ofAce2, Tmprss2, and Ctsl. 
 
Extended Data Figure 14. Additional analyses to identify other proteases that may have a 
role in infection. 
(a) Multiple proteases are co-expressed with ACE2 in another human lung scRNA-seq 
(“aggregated lung”). Scatter plot of significance (y axis, -log10(adjusted p value)) and effect size 
(x axis) of co-expression of each protease gene (dot) with ACE within each indicated epithelial 
cell type (color). Dashed line: significance threshold. TMPRSS2 and PCSKs that significantly co-
expressed with ACE2 are marked. (b) ACE2-protease co-expression with PCSKs, TMPRSS2 and 
CTSL across lung cell types (“aggregated lung”). Significance (dot size, -log10(adjusted p value)) 
and effect size (color) for co-expression of ACE2 with selected proteases (columns) across cell 
types (rows). (c-d) Predicted cleavage sites in the SARS-CoV-2 S-protein S1/S2 region. (c) 
Multiple amino acid sequence alignment of SARS-CoV-2 S-protein S1/S2 region with orthologous 
sequences from other betacoronaviruses (top) and polybasic cleavage sites of other human 
pathogenic viruses (bottom). (d) Sequence logo plot showing cleavage site preference derived 
from MEROPS database for PCSK1, PCSK2, FURIN, PCSK4, PCSK5, PCSK6 and PCSK7. (e) 
Protease cleavage sites (triangles) predicted by ProP and PROSPERous in the SARS-CoV-2 spike 
protein. Top: Full-length SARS-CoV-2 S-protein sequence schematic with predicted functional 
protein domains and motifs. Numbers: amino acid residues after which cleavage occurs; SP: signal 
peptide; NTD: N-terminal domain; RBD: Receptor-binding domain; FP: Fusion peptide; FP1/2: 
Fusion peptide 1/2; HR1: Heptad repeat 1; CH: connecting helix; HR2: Heptad repeat 2; TM: 
Transmembrane domain. (f,g) Multiple proteases are expressed across lung cell types (“aggregated 
lung”). (f) Distribution of expression (y axis) for ACE2, PCSKs and TMPRSS2 across lung cell 
types (x axis). White dot: median expression. (g) Proportion of cells (y axis) expressing ACE2, 
PCSK family or TMPRSS2 across lung cell types (x axis), ordered by compartment. (h) 
ACE2+PCSK+ dual positive cells across lung cell types. Fraction (y axis) of different ACE2+PCSK+ 
or ACE2+TMPRSS2+ dual positive cells across lung cell types, ordered by compartment (x axis). 
Dots: different individuals, line: median. (i,j) ACE2+PCSK+ co-expression across human tissues 
(collection of published scRNA seq datasets). (i) Percent (y axis) of different ACE2+PCSK+ or 
ACE2+TMPRSS2+ dual positive cells across human tissues (x axis). Dots: different individuals, 
line: median. (j) ACE2 co-expression with PCSKs or TMPRSS2 across human tissues. Significance 
(dot size) and effect size (dot color) of co-expression. (k) Fraction of ACE2+TMPRSS2+PCSK+ 
cells across lung cell types (“Regev/Rajagopal dataset”). Dots: individuals, line: median. 
 
Extended Data Figure 15. ACE2-protease co-expression of the top 20 most significantly co-
expressed human proteases in key lung epithelial cell types. 
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Significance (dot size) and effect size (dot color) of co-expression of each protease (columns) with 
ACE2 in each cell subset (rows). 
  
Extended Data Figure 16. Variation in fraction of ACE2+TMPRSS2+ cells 
The normalized fraction of ACE2+TMPRSS2+ cells in 282 lung and nasal samples from 164 donors, 
subdivided by cell type. Normalization was performed by dividing the fraction by the median total 
counts per cell in the cell type of the sample. Samples are grouped by dataset and ordered by donor 
age within each dataset (blue bars at the top). Datasets are ordered by mean age of donors. White 
patches indicate the cell type annotation was not observed in the sample. This occurs either due to 
coarseness of annotation, or absence of cell type in the sample. 
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